



NUVO PHARMACEUTICALS INC.

NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS

NOTICE IS HEREBY GIVEN that the Annual and Special Meeting of Shareholders (the “**Meeting**”) of **NUVO PHARMACEUTICALS INC.** (the “**Corporation**”) will be held on Thursday, May 11, 2017 at 9:00 a.m. (ET) at One King West Hotel, 1 King St. West, Toronto, Ontario for the following purposes:

- (1) to receive the audited financial statements of the Corporation for the fiscal year ended December 31, 2016, together with the auditors’ report thereon;
- (2) to elect directors of the Corporation for the ensuing year;
- (3) to appoint auditors of the Corporation for the ensuing year and to authorize the directors to fix their remuneration;
- (4) to consider, and if thought advisable, to adopt, with or without variation, an ordinary resolution (the full text of which is reproduced as Schedule A to the accompanying Management Information Circular) affirming, ratifying and approving the Corporation’s Third Amended and Restated Share Incentive Plan and approving all unallocated options and unallocated common shares issuable thereunder; and
- (5) to transact such other business as may properly be brought before the Meeting or any adjournment thereof.

DATED at Mississauga, Ontario this 5th day of April, 2017.

BY ORDER OF THE BOARD OF DIRECTORS

A handwritten signature in black ink, appearing to read "John London", with a long horizontal stroke extending to the right.

John London
Chief Executive Officer

Shareholders who are unable to attend the Meeting in person are entitled to be represented at the Meeting by proxy and are requested to complete, date, sign and return the enclosed form of proxy to the Transfer Agent of the Corporation, CST Trust Company, Proxy Department, P.O. Box 721, Agincourt, Ontario M1S 0A1, or by fax: 1-866-781-3111 or 416-368-2502, or by email: proxy@canstockta.com no later than 5:00 p.m. (ET) on Tuesday, May 9, 2017 or in the case of any adjournment of the Meeting, no later than 5:00 p.m. (ET), on the business day immediately preceding the date of such adjournment.

NUVO PHARMACEUTICALS INC.

MANAGEMENT INFORMATION CIRCULAR

SOLICITATION OF PROXIES

This management information circular (the “Circular”) is furnished in connection with the solicitation of proxies by the management of Nuvo Pharmaceuticals Inc. (the “Corporation”) for use at the Annual and Special Meeting of Shareholders of the Corporation (the “Meeting”) to be held on Thursday, May 11, 2017 at 9:00 a.m. (ET) at One King West Hotel, 1 King St. West, Toronto, Ontario and at any adjournment or adjournments thereof, for the purposes set forth in the accompanying Notice of Meeting.

The Corporation will bear the cost of soliciting proxies. Proxies may be solicited by mail and the directors, officers or regular employees of the Corporation may solicit proxies personally, by telephone or by fax. **The solicitation of proxies by this Circular is being made by or on behalf of management of the Corporation.** None of these individuals will receive any extra compensation for such efforts. The Corporation will reimburse banks, trust companies, brokerage firms and other custodians, nominees and fiduciaries (“**Intermediaries**”) for any reasonable expenses incurred in sending proxy material to beneficial owners of shares and requesting authority to execute proxies. Proxy-related materials will be sent by the Corporation to Intermediaries and not directly to non-registered beneficial shareholders. The Corporation intends to pay for Intermediaries to deliver proxy-related materials and the Form 54-101F7 (the request for voting instructions) to “objecting beneficial owners”, in accordance with National Instrument 54-101.

Copies of the Corporation’s latest annual information form (together with the documents incorporated therein by reference), the comparative financial statements of the Corporation for the fiscal year ended December 31, 2016 together with the report of the auditors thereon, management’s discussion and analysis of the Corporation’s financial condition and results of operations for the fiscal year ended December 31, 2016, and this Circular are available upon request from the Corporation without charge to the security holder. The information contained herein is given as of April 5, 2017, except where otherwise noted.

FORWARD LOOKING INFORMATION

Certain statements in this Circular constitute forward-looking information and/or forward-looking statements (collectively, “forward-looking statements”) within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements concerning the Corporation’s future objectives, strategies to achieve those objectives, as well as statements with respect to management’s beliefs, plans, estimates and intentions, and similar statements concerning anticipated future events, results, circumstances, performance or expectations that are not historical facts. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “outlook”, “objective”, “may”, “will”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “should”, “plans” or “continue”, or similar expressions suggesting future outcomes or events. Such forward-looking statements reflect management’s current beliefs and are based on information currently available to management. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those contemplated by such statements. Factors that could cause such differences include general business and economic uncertainties and adverse market conditions as well as other risk factors included in the Corporation’s Annual Information Form for the year ended December 31, 2016 and as described from time to time in the reports and disclosure documents filed by the Corporation with Canadian securities regulatory agencies and commissions. This list is not exhaustive of the factors that may impact the Corporation’s forward-looking statements. These and other factors should be considered carefully and readers should not place undue reliance on the Corporation’s forward-looking statements. As a result of the foregoing and other factors, there can be no assurance that actual results will be consistent with these forward-looking statements, and neither the Corporation nor any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. All forward-looking statements in this Circular are qualified by these cautionary statements. The forward-looking statements contained herein are made as of the date of this Circular and except as required by applicable law, the Corporation undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

APPOINTMENT AND REVOCATION OF PROXIES

Registered Holders

A registered shareholder is a shareholder who holds common shares of the Corporation (“**Common Shares**”) in his, her or its own name (that is, not in the name of, or through an Intermediary).

A registered shareholder may attend the Meeting and cast one vote for each Common Share registered in the name of such registered shareholder on any and all resolutions put before the Meeting. A registered shareholder who is unable to attend the Meeting, or does not wish to personally cast his, her or its vote(s), may authorize another person at the Meeting to vote on his, her or its behalf. This is known as voting by proxy. The form of proxy enclosed with the Circular may be used by registered shareholders to authorize another person to vote on their behalf at the Meeting.

The persons named in the form of proxy are directors and/or officers of the Corporation. A shareholder of the Corporation who wishes to appoint some other person to represent him, her or it at the Meeting may do so by striking out the names of the persons specified in the form of proxy and inserting the name of the person to be appointed in the blank space so provided.

To be valid, completed proxies must be delivered to the transfer agent of the Corporation, CST Trust Company, Proxy Department, P.O. Box 721, Agincourt, Ontario M1S 0A1, or by fax: 1-866-781-3111 or 416-368-2502, or by email: proxy@canstockta.com no later than 5:00 p.m. (ET) on Tuesday, May 9, 2017 or in the case of any adjournment of the Meeting, no later than 5:00 p.m. (ET) on the business day immediately preceding the date of such adjournment, or to the Chairperson of the meeting at any time prior to the commencement of the meeting or any adjournment thereof.

A registered shareholder who executes and returns a form of proxy may revoke it by depositing an instrument in writing executed by such shareholder or such shareholder’s attorney authorized in writing at the head office of the Corporation, 7560 Airport Road, Unit 10, Mississauga, Ontario, L4T 4H4, Attention: John London, Chief Executive Officer, at any time up to and including the last business day preceding the Meeting or any adjournment thereof or by depositing such instrument in writing with the Chairman of the Meeting on the day of the Meeting or any adjournment thereof, or in any other manner permitted by law.

Non-Registered Holders

Information set forth in this section is very important to persons who hold Common Shares other than in their own names. Only registered holders of Common Shares, or the persons they appoint as their proxies, are permitted to attend and vote at the Meeting. However, in many cases, Common Shares beneficially owned by a holder (a “**Non-Registered Holder**”) are registered either:

- (a) in the name of an Intermediary that the Non-Registered Holder deals with in respect of the shares; or
- (b) in the name of a depository (a “**Depository**” such as The Canadian Depository for Securities Limited) of which the Intermediary is a participant.

Such Intermediary is the registered holder of the Non-Registered Holder’s Common Shares and is the entity legally entitled to vote these shares at the Meeting. In order for a Non-Registered Holder to vote his, her or its Common Shares at the Meeting, they must carefully follow the procedures and instructions received from the Intermediary.

In accordance with the requirements of Canadian securities law, the Corporation has distributed copies of the Notice of Meeting, this Circular, the form of proxy and the Report to Shareholders for the fiscal year ended December 31, 2016 (collectively, the “**meeting materials**”) to Depositories and Intermediaries for onward distribution to Non-Registered Holders.

Intermediaries are required to forward meeting materials to Non-Registered Holders unless a Non-Registered Holder has waived the right to receive them. Very often, Intermediaries will use service companies to forward the meeting

materials to Non-Registered Holders. Generally, Non-Registered Holders who have not waived the right to receive meeting materials will either:

- (a) be given a form of proxy which has already been signed by the Intermediary (typically by a facsimile, stamped signature), which is restricted as to the number of Common Shares beneficially owned by the Non-Registered Holder but which is otherwise not completed. This form of proxy need not be signed by the Non-Registered Holder. In this case, the Non-Registered Holder who wishes to submit a proxy should otherwise properly complete the form of proxy and deposit it with the Corporation c/o CST Trust Company, Proxy Department, P.O. Box 721, Agincourt, Ontario M1S 0A1, or by fax: 1-866-781-3111 or 416-368-2502, or by email: proxy@canstockta.com, as described above; or
- (b) more typically, be given a voting instruction form which must be completed and signed by the Non-Registered Holder and returned to the Intermediary in accordance with the directions on the voting instruction form (which may in some cases permit the completion of the voting instruction form by telephone or online).

The purpose of these procedures is to permit Non-Registered Holders to direct the voting of the Common Shares they beneficially own. Although Non-Registered Holders may not be recognized directly at the Meeting for the purposes of voting Common Shares registered in the name of an Intermediary, a Non-Registered Holder may attend the Meeting as proxy holder for the registered shareholder (i.e. the Intermediary) and vote their Common Shares in that capacity. A Non-Registered Holder who wishes to attend and vote at the Meeting in person and indirectly vote his or her Common Shares as proxy holder for the registered holder (or have another person attend and vote on behalf of the registered holder), should strike out the names of the persons named in the proxy and insert the name of the Non-Registered Holder in the blank space provided or, in the case of a voting instruction form, follow the corresponding instructions on the form. *In either case, Non-Registered Holders should carefully follow the instructions of their Intermediaries and their service companies.*

VOTING AND EXERCISE OF DISCRETION BY PROXIES

All properly executed forms of proxy, not previously revoked, will be voted or withheld from voting at the Meeting in accordance with the instructions contained therein on any ballot that may be called for. **Forms of proxy containing no instructions regarding the matters specified therein will be voted in favour of such matters. In the event, not presently anticipated, that any other matter is brought before the Meeting and is submitted to a vote, the form of proxy may be voted in accordance with the judgment of the persons named therein.** The form of proxy also confers discretionary authority in respect of amendments to or variations in all matters that may properly come before the Meeting.

Record Date

The board of directors of the Corporation (the “**Board**”) has fixed March 29, 2017 as the record date (the “**Record Date**”) for determining the shareholders entitled to receive notice of the Meeting and, accordingly, only shareholders of record on the Record Date are entitled to receive notice of and vote at the Meeting.

Interest of Certain Persons in Matters to be Acted Upon

Other than with respect to the election of directors and participation in the Corporation’s Share Incentive Plan (as defined herein), none of the Corporation’s directors or senior officers, or any associate or controlled corporation of any such person has any direct or indirect material interest in any of the matters to be acted upon at the Meeting.

VOTING SECURITIES AND PRINCIPAL HOLDERS THEREOF

As of the Record Date, the Corporation had outstanding 11,550,897 Common Shares, each carrying one vote.

To the knowledge of the directors and officers of the Corporation, as of the Record Date, no person beneficially owns, directly or indirectly, or exercises control or direction over, Common Shares carrying more than 10% of the voting rights attached to the outstanding Common Shares.

BUSINESS TO BE TRANSACTED AT THE MEETING

Financial Statements and Auditors' Report

Management, on behalf of the Board, will submit to the shareholders at the Meeting the audited consolidated financial statements of the Corporation for the fiscal year ended December 31, 2016, and the report of the auditors thereon, but no vote by the shareholders with respect thereto is required or proposed to be taken. The audited consolidated financial statements and Auditors' report form part of the Report to Shareholders for the fiscal year ended December 31, 2016 which is being mailed to those shareholders that have requested such materials with the Notice and this Circular and which is available at www.sedar.com.

Election of Directors

The Board has adopted a majority voting policy in director elections that will apply at any meeting of shareholders where an "uncontested election" of directors is held. Pursuant to this policy, if the number of proxy votes withheld for a particular director nominee is greater than the votes for such director, the director nominee will be required to submit his or her resignation to the Board. Following the receipt of a director's resignation, the Compensation, Corporate Governance and Nominating Committee will consider whether or not to accept the offer of resignation. With the exception of special circumstances, the Compensation, Corporate Governance and Nominating Committee will be expected to recommend that the Board accept the resignation. Within 90 days following the Corporation's meeting of shareholders, the Board will make its decision and disclose it by a press release, such press release to include the reasons for rejecting the resignation, if applicable. A director who tenders his or her resignation pursuant to this majority voting policy will not be permitted to participate in any meeting of the Board or the Compensation, Corporate Governance and Nominating Committee at which the resignation is considered. The Board has adopted an individual director voting policy. Under this policy, shareholders will be asked to vote for each individual director rather than a slate of directors. The persons named in the enclosed form of proxy intend to vote for the election of each of the six nominees to the Board whose names are set forth below. Management does not contemplate that any of the nominees will be unable to serve as a director; if that should occur for any reason at or prior to the Meeting, the persons named in the enclosed form of proxy reserve the right to vote for another nominee in their discretion. Each director elected will hold office until the next annual meeting or until his successor is elected or appointed.

Pursuant to the Corporation's By-Law Number 2 (the "**Advance Notice By-Law**"), Shareholders who wish to nominate directors to the Board must submit a notice of such nominations (along with certain other prescribed information) to the Corporation prior to any annual or special meeting of Shareholders where Directors are to be elected. The Advance Notice By-Law allows the Corporation and its Shareholders to receive adequate prior notice of director nominations, as well as sufficient information on all of the nominees. The purpose of the Advance Notice Policy is not to discourage Shareholder nominations, but rather to facilitate an organized and efficient meeting process. This ensures that all Shareholders, including those voting by proxy, receive adequate notice of the nominations and have an opportunity to register an informed vote having been afforded a reasonable amount of time for consideration. In the case of an annual meeting of Shareholders (such as the Meeting), notice to the Corporation of a proposed nominee must be provided not less than 30 days and not more than 65 days prior to the date of the annual meeting. Accordingly, the deadline for a Shareholder to nominate an individual for election as a director of the Corporation at the Meeting is April 11, 2017. The full text of the Advance Notice By-Law is available at www.sedar.com.

The following table sets forth the names of all persons proposed to be nominated by management for election as director, all positions and offices with the Corporation now held by them, if applicable, their principal occupations or employment, the point in time at which they became directors of the Corporation and the number of Common Shares and convertible securities of the Corporation beneficially owned, directly or indirectly, by each of them or over which each of them exercises control or direction as of April 5, 2017. In addition, the table sets forth the members of the Corporation's Compensation, Corporate Governance and Nominating Committee and Audit Committee.

Samira Sakhia, a director of the Corporation since October 29, 2015 and the current Chair of the Audit Committee, will not be standing for re-election due to other commitments.

<u>Name and Residence</u>	<u>Principal Occupation</u>	<u>Director Since</u>	<u>Number of Common Shares Beneficially Owned or Controlled</u>
Daniel Chicoine ^(4, 8) Ontario, Canada	Chairman of Company; Executive Chairman & Interim CEO, Crescita Therapeutics Inc.	September 21, 2004	235,784
David A. Copeland ^(5, 6, 7, 9) Ontario, Canada	Private Business Consultant	September 21, 2004	57,692
Anthony E. Dobranowski ^(1, 3) Ontario, Canada	Private Business Consultant	September 21, 2004	47,085
Robert P. Harris Ontario, Canada	Director, Aralez Pharmaceuticals Inc. and CannaRoyalty Corp.	N/A	0
John C. London ⁽⁶⁾ Ontario, Canada	Chief Executive Officer	September 21, 2004	155,786
Dr. Jacques Messier ⁽²⁾ Ontario, Canada	CEO, The Toronto Humane Society	September 21, 2004	34,523

Notes:

- (1) Member of the Compensation, Corporate Governance and Nominating Committee.
- (2) Chairman of the Compensation, Corporate Governance and Nominating Committee.
- (3) Member of the Audit Committee.
- (4) Daniel Chicoine was a director of NRI Industries Inc. (“NRI”), a company primarily involved in the manufacture of rubber and plastic components for automotive and industrial applications, until August 23, 2006, when he resigned. This company filed for protection pursuant to the *Companies’ Creditors Arrangement Act* (“CCAA”) on September 5, 2006. On April 27, 2007, subsequent to the sale of substantially all of the assets of NRI, the CCAA proceedings were terminated and NRI filed its assignment into bankruptcy and in July 2008 the government cancelled the Corporation for cause.
- (5) David Copeland was Chairman of the Board of Triton Electronik, a group of Canadian companies primarily involved in electronic contract design and manufacturing service, until January 2009, when he resigned. This group of companies filed for protection pursuant to the CCAA on January 28, 2009.
- (6) John London and David Copeland were directors of MTB Industries Inc. (“MTB”) until May 1, 2009 when they both resigned. MTB filed for court appointed receivership on May 5, 2009.
- (7) Lead Director.
- (8) Chairman.
- (9) Chairman of the Audit Committee.

Each of the nominated directors of the Corporation has been engaged for more than five years in his present principal occupation or in other capacities with the Corporation (or predecessor thereof) in which he currently holds his or her principal occupation, with the exception of the following: Daniel Chicoine who from November 2004 to March 2016 was the Co-CEO of Nuvo Pharmaceuticals Inc. and since March 2016 is the Executive Chairman & Interim CEO of Crescita Therapeutics Inc. and Robert Harris who from December 2011 to February 2016 was the CEO and a director of Tribute Pharmaceuticals Canada Inc. and since February 2016 has been a director of Aralez Pharmaceuticals Inc. and since December 2016 has been a director of CannaRoyalty Corp.

As of December 31, 2016, the Board consisted of six directors, the majority of which are independent under applicable securities laws. There are six directors proposed to be nominated by management for election as director, the majority of which are independent under applicable securities laws.

Appointment of Auditors

At the Meeting, shareholders will be asked to appoint Ernst & Young LLP as the auditors of the Corporation (the “Auditors”), based on the recommendations of the Audit Committee and the Board. Ernst & Young LLP was appointed as the Auditors by the Audit Committee and the Board on August 9, 2012. The persons named in the accompanying form of proxy will, in the absence of specific instructions to withhold from voting on the proxy, vote for the appointment of Ernst & Young LLP as the Auditors of the Corporation to hold office until the next annual meeting of shareholders of the Corporation and to authorize the Audit Committee of the Board to fix the Auditors’ remuneration.

INTERESTS OF INFORMED PERSONS IN MATERIAL TRANSACTIONS

To the knowledge of the Corporation, other than as disclosed elsewhere in this Circular, no director or officer of the Corporation, any subsidiary or any insider, nominee director, shareholder owning more than ten percent of the

Common Shares, or any associate or affiliate of any of the foregoing has had any interest in any transaction since the commencement of the Corporation's last financial year or in any proposed transaction that has materially affected or would materially affect the Corporation or any of its subsidiaries.

STATEMENT OF EXECUTIVE COMPENSATION

Under Form 51-102F6 in National Instrument 51-102, the Corporation's Chief Executive Officer ("CEO"), Chief Financial Officer ("CFO") and each of the three most highly compensated executive officers or other individuals acting in a similar capacity are termed Named Executive Officers ("NEOs") for whom the Corporation must disclose certain financial and other information relating to compensation. The NEOs of the Corporation for the year ended December 31, 2016 are: (i) Daniel Chicoine; (ii) John London; (iii) Stephen Lemieux; (iv) Mary-Jane Burkett; (v) Jesse Ledger; (vi) Calogero Lunetta; and (vii) Henrich Guntermann. Mr. Chicoine is included as an NEO as he was Co-CEO of the Corporation during 2016. He resigned from this position on March 1, 2016. Mr. Lemieux is included as an NEO as he was CFO of the Corporation during 2016. He resigned from this position on September 9, 2016.

Unless otherwise specifically stated, the information in this section is given as of, or in respect of the applicable period ending, December 31, 2016.

Compensation Discussion and Analysis

The Corporation's executive compensation program is administered by the Compensation, Corporate Governance and Nominating Committee which is comprised entirely of independent directors. During 2015 and up to March 1, 2016, the members of the Compensation, Corporate Governance and Nominating Committee were Jacques Messier, Anthony Dobranowski, Theodore Stanley and Klaus von Lindeiner. As of March 1, 2016, the members of the Compensation, Corporate Governance and Nominating Committee were Jacques Messier, Samira Sakhia and Anthony Dobranowski. The Board recognizes the importance of appointing knowledgeable and experienced individuals to this Committee. Thus, most members of the Compensation, Corporate Governance and Nominating Committee have significant experience in executive compensation and risk management as senior leaders of complex organizations or through their prior and current membership on the Compensation, Corporate Governance and Nominating Committee or other boards. For example, Dr. Messier has periodically participated in corporate governance courses and has served as a senior executive in a number of organizations that have reviewed executive compensation and management incentive plans; Mr. Dobranowski is a Canadian Chartered Professional Accountant, has participated in governance courses periodically and has served as a senior executive in a number of organizations that have reviewed executive compensation and management incentive plans; Dr. von Lindeiner holds a legal designation in Germany, has participated in governance courses periodically and has served on boards where executive compensation and management incentives plans were reviewed and approved at the board level; Dr. Stanley has served as a senior leader in a number of organizations that have reviewed executive compensation and management incentive plans; and Ms. Sakhia is a Canadian Chartered Professional Accountant and has served as a senior executive that has reviewed executive compensation and management incentive plans.

The Compensation, Corporate Governance and Nominating Committee's mandate is set out in the Compensation, Corporate Governance and Nominating Committee Charter approved by the Board. Responsibilities included in the Compensation, Corporate Governance and Nominating Committee's mandate are to:

- develop a compensation structure for the Board and senior management, including salaries, annual and long-term incentive ("LTI") plans and plans involving share options, share issuances and share unit awards;
- review the compensation and performance of senior management at least annually, with a view to maintaining a compensation program for senior management at a fair and competitive level, consistent with the best interests of the Corporation; and
- periodically review the compensation of directors to, among other things, ensure their compensation appropriately reflects the responsibilities they are assuming.

Additional information relating to the mandate of the Compensation, Corporate Governance and Nominating Committee is included under the heading "Statement of Corporate Governance" below.

In discharging its mandate, the Compensation, Corporate Governance and Nominating Committee has the authority to retain and receive advice from outside advisors. In 2010, the Compensation, Corporate Governance and Nominating Committee (then the Compensation and Corporate Governance Committee) engaged Radford Consulting (“**Radford**”), a consulting division of Aon Corporation (“**AON**”), to evaluate its executive compensation program and provide expert advice and recommendations to ensure that the Corporation’s executive compensation program is competitive in the industry segment in which the Corporation participates. The table below shows the fees paid to Radford or its consulting division, AON, over the past two years. In 2015, \$7,088 was paid to Radford for access to a life sciences compensation database and in 2016, \$10,000 was paid to AON for consulting work.

	2015	2016
Executive Compensation-related Fees	Nil	Nil
All Other Fees	\$7,088	\$10,000

a) Objective of Compensation Program

Within the Corporation, executive remuneration is designed to encourage, compensate and reward employees on the basis of individual and corporate performance, both in the short and long-term. Compensation is directly tied to corporate and individual performance.

The level of remuneration, including annual and long-term compensation, for each NEO at this stage of the Corporation’s development is determined by the level of responsibility, level of experience and the importance of the position to the Corporation, all with a view to being consistent with industry norms. Further, the Share Incentive Plan, including options to acquire Common Shares, are designed to give each optionee an interest in preserving and maximizing shareholder value in the longer term, to enable the Corporation to attract and retain individuals with experience and ability, and to reward individuals for current performance and expected future performance. In the view of the Compensation, Corporate Governance and Nominating Committee, options and other LTIs, the value of which is related to the Corporation’s share price, align the interests of executive officers with the longer term interests of shareholders. In determining the number of Common Shares subject to each option or other form of LTI, the Compensation, Corporate Governance and Nominating Committee gives consideration to the individual’s present and potential contribution to the success of the Corporation.

The Board, in consultation with the Compensation, Corporate Governance and Nominating Committee, periodically identifies the principal risks of the Corporation’s business and ensures the implementation of appropriate systems and controls to manage these risks. This would include risks associated with the Corporation’s compensation practices, if any. The Corporation does not feel that its compensation practices would encourage an executive officer to take inappropriate or excessive risks, and no particular risks have been identified as arising from the Corporation’s compensation practices that are reasonably likely to have a material adverse effect on the Corporation.

The Compensation, Corporate Governance and Nominating Committee endeavors to design the compensation program to ensure that the executive officers do not take unnecessary and excessive risks that could harm the long-term value of the Corporation. The following components of the compensation program discourage the executive officers from taking unnecessary or excessive risks:

- Base salaries are sufficiently competitive and are not subject to performance risk.
- Compensation includes compensation based on achievement of a combination of short and long-term objectives approved by the Compensation, Corporate Governance and Nominating Committee and the Board.
- The vesting period of equity based LTI awards are preferably three years in length or longer.
- The annual incentive based awards and performance based equity awards are based on achieving objectives approved by the Compensation, Corporate Governance and Nominating Committee and the Board.

As discussed above, the Compensation, Corporate Governance and Nominating Committee originally retained Radford in 2010 to ensure that the Corporation’s executive compensation program is competitive in the industry segment in which the Corporation participates. To this end, Radford, in collaboration with the Compensation, Corporate Governance and Nominating Committee, identified a number of companies in the life sciences industry in Canada and the United States that at the time were comparable to the Corporation (the “**Comparator Group**”). The Comparator Group consists of the following companies and is based on a number of factors, including stage of drug development, market capitalization, revenue and number of employees as of 2010:

Comparator Group Companies – Canada	Comparator Group Companies – United States
AEterna Zentaris Inc.	ACADIA Pharmaceuticals Inc.
Bioniche Life Sciences Inc.	Adolor Corporation
Cardiome Pharma Corp.	Alexza Pharmaceuticals, Inc.
Generex Biotechnology Corporation	Amicus Therapeutics, Inc.
Labopharm Inc.	Antigenics, Inc.
Paladin Labs Inc.	ARIAD Pharmaceuticals, Inc.
ProMetic Life Sciences Inc.	BioCryst Pharmaceuticals, Inc.
QLT Inc.	Columbia Laboratories, Inc.
Tekmira Pharmaceuticals Corporation	DepoMed, Inc.
Theratechnologies Inc.	DURECT Corporation
YM BioSciences Inc.	Dyax Corp.
	EpiCept Corporation
	GenVec, Inc.
	GTx, Inc.
	Idenix Pharmaceuticals, Inc.
	Ligand Pharmaceuticals Incorporated
	NeurogesX, Inc.
	Pain Therapeutics, Inc.
	Poniard Pharmaceuticals, Inc.
	POZEN Inc.
	Progenics Pharmaceuticals, Inc.
	Vical Incorporated
	XenoPort, Inc.

In 2013, the Compensation, Corporate Governance and Nominating Committee formed a subcommittee (the “**Subcommittee**”) to make recommendations to the Compensation, Corporate Governance and Nominating Committee and the Board respecting LTI. The Subcommittee was of the opinion that an update to the Radford report and recommendations on executive compensation conducted in 2010 (the “**Radford Report**”) might be helpful to the Subcommittee. The Subcommittee determined that it was in the best interests of the Corporation to not incur any external cost for evaluations by Radford for the 2013 year and, accordingly, requested that the finance department of the Corporation use publicly available information to a) update the compensation information from the comparator group of companies identified in the Radford Report and b) prepare an executive compensation comparison based on a new peer group of Canadian small cap life sciences companies (“**2012 Canadian Small Cap Companies**”). It was felt by the Compensation, Corporate Governance and Nominating Committee that the combination of these information sources would be helpful to the Subcommittee and the Compensation, Corporate Governance and Nominating Committee in developing recommendations for the Board for the Corporation’s Canadian based executive management. The requested evaluation of Canadian Small Cap Companies compared the 2012 compensation of a new Canadian small cap life sciences peer group of companies to the compensation then

being earned by the Corporation's executive management team in 2012. The Canadian Small Cap Companies consists of the following Canadian companies in the life sciences industry that are listed on the TSX, and was established based on a number of additional factors, including stage of drug development, a market capitalization of less than \$50 million at the time of the assessment, revenue and number of employees as of 2012, in an effort to identify those small cap Canadian companies that were most similar to the Corporation:

2012 Canadian Small Cap Companies
AEterna Zentaris Inc.
Bellus Health Inc.
Bioniche Life Sciences Inc.
Cardiome Pharma Corp.
IntelliPharmaCeutics International Inc.
Isotechnika Pharma Inc.
Lorus Therapeutics Inc.
Resverlogix Corp.
Sophiris Bio Inc.
Theratechnologies Inc.

For the Canadian-based executives Daniel Chicoine (former Co-CEO), John London, and Stephen Lemieux (former CFO), the Subcommittee referred to the Radford Report, the update to the Radford Report and the report based on the Canadian Small Cap Companies. However, the Subcommittee felt that comparator information from Canadian Small Cap Companies was less relevant for executives who did not reside or oversee operations in Canada (i.e. Dr. Guntermann (former Group President), who oversaw the drug development activities in Germany). Accordingly, in reviewing the compensation for Dr. Guntermann, the Compensation, Corporate Governance and Nominating Committee referred to the Radford Report and the update to the Radford Report.

In 2016, the Board, on the recommendation of the Compensation, Corporate Governance and Nominating Committee, used the same LTI benchmark data as in 2013 in reviewing executive management LTI awards, which is set out below.

CEO Role – The following benchmarks were used for each of Mr. Daniel Chicoine (former Co-CEO) and Mr. John London and not in aggregate.

	BOD Compensation Target based on 2010 Radford Report	Radford Peer Group Average 2012	New Canadian Peer Group Average 2012
Cash Compensation	562,500	723,324	465,532
LTI Compensation	241,700	745,902	324,851
Total Compensation	804,200	1,469,226	790,383

Former Vice President & CFO – Mr. Stephen Lemieux

	BOD Compensation Target based on 2010 Radford Report	Radford Peer Group Average 2012	New Canadian Peer Group Average 2012
Cash Compensation	326,200	391,039	300,600
LTI Compensation	136,300	291,916	65,724
Total Compensation	462,500	682,955	366,324

Former Group President – Dr. Henrich Guntermann

	BOD Compensation Target based on 2010 Radford Report	Radford Peer Group Average 2012	New Canadian Peer Group Average 2012
Cash Compensation	481,250	413,472	n/a
LTI Compensation	118,150	373,786	n/a
Total Compensation	599,400	787,258	n/a

Ms. Mary-Jane Burkett was appointed Vice President and CFO on September 12, 2016 to replace Mr. Stephen Lemieux. The Compensation, Corporate Governance and Nominating Committee used several benchmarking tools to determine Ms. Burkett’s compensation, including an AON report that included a comparator group of Canadian and U.S. companies, information extracted from the Radford Life Sciences database of Canadian companies and a Canadian based peer group that consisted of the comparable companies listed in the following table (“**2016 Canadian Small Cap Companies**”). Ms. Burkett’s compensation was set taking into account these benchmarking tools and her experience.

2016 Canadian Small Cap Companies
ESSA Pharma Inc.
Cipher Pharmaceuticals Inc.
BioSyent Inc.
Merus Labs International Inc.
Profound Medical Corp.
IntelliPharmaCeutics International Inc.
Trillium Therapeutics Inc.
Transition Therapeutics Inc.

Mr. Jesse Ledger was appointed President on November 15, 2016. The Compensation, Corporate Governance and Nominating Committee used several benchmarking tools to determine Mr. Ledger's compensation, including an AON report that included a comparator group of Canadian and U.S. companies, information extracted from the Radford Life Sciences database of Canadian companies and a Canadian based peer group that consisted of the 2016 Canadian Small Cap Companies. Mr. Ledger's compensation was set taking into account these benchmarking tools, his experience and his anticipated value to the Company given its strategy of diversification.

In 2016, the Compensation, Corporate Governance and Nominating Committee used data from the Radford Life Sciences database to assess Mr. Calogero Lunetta's annual cash compensation. The Compensation, Corporate Governance and Nominating Committee decided that although Mr. Lunetta's cash compensation component is significantly less than the benchmark target from the Radford Life Sciences database, his compensation also includes a profit sharing element. Under this program, Mr. Lunetta receives 1.25% of the pre-tax earnings generated by the Corporation's manufacturing facility in Varennes, Quebec. The Committee was of the view that given Mr. Lunetta's direct responsibility to maximize profits at the Corporation's manufacturing facility, a significant portion of his compensation should be tied to those profits.

While benchmarking is not the sole methodology used by the Compensation, Corporate Governance and Nominating Committee in reaching its executive compensation decisions, the information obtained from the Radford Life Sciences database and comparator company groups as described above is helpful in determining whether the Corporation's executive compensation package is competitive and reasonable *vis a vis* the market. The Compensation, Corporate Governance and Nominating Committee believes that this process provides a suitable mechanism to ensure executive compensation remains competitive relative to the industry and facilitates timely adjustments to compensation packages to achieve the objectives of the compensation program.

b) What the Compensation Program is Designed to Reward

Plans and programs are designed so as to constitute adequate reward for services and incentive for the senior management team to implement both short-term and long-term strategies aimed at creating economic value for the Corporation, increasing share value and balancing risk management. The Corporation utilizes an annual business planning process that identifies annual corporate and departmental goals which are reviewed and approved by the Board. The executive management team's performance, including the performance of the NEOs, is reviewed relative to achievement of these goals.

c) Elements of Compensation Program, Determination of Amounts for each Element, Rationale for Amounts of each Element

The major elements of the Corporation's executive compensation program are (i) base salary, (ii) annual incentive awards based on achieving corporate objectives approved by the Compensation, Corporate Governance and Nominating Committee and the Board ("**Corporate Objectives**") and in the case of Ms. Burkett, also Departmental Objectives, and Mr. Lunetta, a profit sharing element; and (iii) LTI awards, which consist of options issued pursuant to the Share Incentive Plan. Prior to the Reorganization, LTI awards also included share appreciation rights ("**Share Appreciation Rights**" or "**SARs**"), which were historically awarded through the Corporation's Share Appreciation Rights Plan (the "**Share Appreciation Rights Plan**"). In addition, the Corporation provides the NEOs with a package of medical benefits, the cost of which is partially paid for by the NEOs, and a car allowance. The compensation policies and guidelines for the NEOs were developed, in part, with assistance from Radford and are reviewed and approved by the Compensation, Corporate Governance and Nominating Committee and the Board. The Board has discretion, at the end of each fiscal year, to increase, decrease, or defer the payment of any annual incentive awards that otherwise might be earned during the year based on achievement of Corporate Objectives taking into consideration movement in the stock price and the financial position of the Corporation when determining amounts payable, timing of payments as well as form of payment.

On March 1, 2016 (the "**Effective Date**"), Nuvo Research Inc. ("**Nuvo Research**") completed a transaction (the "Reorganization") pursuant to which Nuvo Research was reorganized into two separate publicly-traded companies, the Corporation and Crescita Therapeutics Inc. ("**Crescita**"). Detailed information regarding the Reorganization and its effects, including a description of certain risks and uncertainties in respect of the Reorganization and the operation of the Corporation and Crescita as separate publicly-traded companies, are included in the management information circular of Nuvo Research dated December 31, 2015 (the "**Reorganization Circular**") that is available

under the Corporation's profile at www.sedar.com. In connection with the Reorganization, various elements of the Corporation's executive compensation program were amended with effect as of the Effective Date, including, among other things, the Share Incentive Plan and Share Appreciation Rights Plan. Copies of the amended and restated Share Incentive Plan and Share Appreciation Rights Plan are available under the Corporation's profile at www.sedar.com. These amendments also are described in greater detail below.

COMPENSATION PHILOSOPHY

As described above, with the benefit of several benchmarking tools, the Compensation, Corporate Governance and Nominating Committee adopted the following compensation philosophy to govern pay decisions for the NEOs and other senior executives:

- To determine competitiveness of compensation, the compensation awarded to NEOs and other senior executives should be compared to compensation for the companies included in the Radford Report, the update to the Radford Report in 2013, the report based on the Canadian Small Cap Companies, and 2016 compensation information from the Radford Life Sciences database and comparator company information. Target pay positioning for the NEOs and other senior executives should approximate:
 - Base Salary – 25th to 50th percentile
 - Annual Incentive Awards – 50th percentile
 - LTI Awards – 50th percentile

Base Salary

Salaries for the NEOs and other senior executives are paid within a salary range established on the basis of the level of responsibility of the executive relative to other positions in the Corporation as well as the experience and knowledge of the executive, with a view to market competitiveness. On the recommendation of Radford in 2010, the Compensation, Corporate Governance and Nominating Committee and the Board approved targeting a base salary for the NEOs between the 25th and 50th percentile of the Comparator Group. Radford further recommended that the base salary of Dr. Guntermann, formerly President & Chief Executive Officer of the Corporation and formerly the President, Europe and Immunology Group, remain unchanged at a level above the target range, based on his history with the Corporation. Radford also recommended that to account for the fact that the Corporation had Co-CEOs the compensation benchmark for each of Messrs. Chicoine and London should be reduced by 10% from what it otherwise would have been for a sole CEO. In 2010, the base salary structure was established by the Compensation, Corporate Governance and Nominating Committee with the benefit of the Radford Report. For 2015, the Compensation, Corporate Governance and Nominating Committee considered the Radford Report, the update to the Radford Report in 2013 and the report based on the Canadian Small Cap Companies and further considered the changes in the core Canadian Consumer Price Index. Based on this analysis, the Board, on recommendation from the Compensation, Corporate Governance and Nominating Committee agreed to a 5% increase in base salary for Dr. Guntermann (former Group President), Mr. London and Mr. Chicoine (former Co-CEO) and a 3% increase in base salary for Mr. Lemieux. As mentioned above, Mr. Chicoine resigned as Co-CEO effective March 1, 2016, Dr. Guntermann resigned as Group President effective March 1, 2016 and Mr. Lemieux resigned as Vice President and CFO effective September 9, 2016. The base salaries of Mr. Chicoine, Dr. Guntermann and Mr. Lemieux did not change in 2016 and they ceased to receive a salary as of their effective date of resignation. The base salary of Mr. London was unchanged in 2016. Ms. Burkett was appointed Vice President and CFO on September 12, 2016. As described above, her experience and several benchmarking tools, including an AON report that included a comparator group of Canadian and U.S. companies, information extracted from the Radford Life Sciences database of Canadian companies and a Canadian based peer group that consisted of the 2016 Canadian Small Cap Companies, were used to set her annual base salary. Mr. Ledger was appointed President on November 15, 2016, and his base salary, as described above, was set using his experience, value to the Corporation and several benchmarking tools, including an AON report that included a comparator group of Canadian and U.S. companies, information extracted from the Radford Life Sciences database of Canadian companies and a Canadian based peer group that consisted of the 2016 Canadian Small Cap Companies. Mr. Lunetta's base salary was examined in 2016 using a benchmarking tool from the Radford Life Sciences database. His base salary increased by 1.5% in 2016 as compared to 2015 for a cost of living adjustment.

Annual Incentive Awards

The Corporation's executive compensation program provides the NEOs and other key employees with the opportunity to earn annual incentive awards based on achieving Corporate Objectives (as defined herein) in the case of Mr. London and Mr. Ledger, a combination of Corporate Objectives and Departmental Objectives (as defined herein) in the case of Ms. Burkett or, a combination of Corporate Objectives and a profit sharing element in the case of Mr. Lunetta. Annual incentive awards are designed to increase alignment with the Corporation's strategic and operational goals.

The Corporate Objectives for 2016 were established by the Compensation, Corporate Governance and Nominating Committee and the Board. They included 3 objectives which were weighted equally at 33⅓% respectively. The first objective was related to the Corporation's out-licensing initiatives for Pennsaid 2%, the second objective was related to the Corporation's strategy to diversify the Corporation's business and the third objective was related to operational efficiencies (collectively, the "**Corporate Objectives**"). For each Corporate Objective, there were performance levels set. Upon meeting, partially meeting or exceeding the threshold performance level for a fiscal year, participants become eligible for an incentive award determined as a percentage of their annual base salary with an ability to earn up to one and a half times the target bonus if the maximum performance level was achieved. The performance levels were assessed as of March 31, 2017.

Mr. Chicoine, Mr. Lemieux and Dr. Guntermann resigned in 2016 and did not receive an annual incentive award. Mr. London's and Mr. Ledger's annual incentive awards were fully based on achieving the Corporate Objectives. Mr. Lunetta's annual incentive award was based on achieving Corporate Objectives and a profit sharing element,

which is described in more detail below. Ms. Burkett's annual incentive award was partially based on achieving Departmental Objectives (described in more detail below) and partially based on the Corporate Objectives.

Based on the Radford Report, participating NEOs are assigned a target bonus (as a percentage of base salary) based on their responsibility level and a benchmark at the 50th percentile of the Comparator Group. In 2016, the Compensation, Corporate Governance and Nominating Committee considered the Radford Report, the update to the Radford Report in 2013 and the report based on the Canadian Small Cap Companies and determined that this structure should not change and the Board approved a target bonus range for the NEOs between 40% and 50% of base salary. The exception to this target range was for Ms. Burkett, who was appointed Vice President and CFO on September 12, 2016. For Ms. Burkett, a target bonus range of 15% was set on Departmental Objectives related to her position as Corporate Controller and her base salary as Corporate Controller and 15% was set using the Corporate Objectives and her base salary as Vice President and CFO.

For 2016, the Corporation fully met the first Corporate Objective related to the Corporation's out-licensing initiatives for Pennsaid 2% and the third objective related to operational efficiencies, such that the awards for those objectives were 100% each. The Corporation did not meet the second Corporate Objective related to the Corporation's strategy to diversify the Corporation's business, such that the award for this objective was 0%. The total award earned based on Corporate Objective achievement for 2016 was 66⅔% of 50% of his base salary for Mr. London, 66⅔% of 30% of her base salary prorated for 6 months as Vice President and CFO for Ms. Burkett, 66⅔% of 30% of his prorated base salary while Mr. Ledger was Vice President, Business Development and 66⅔% of 40% of his prorated base salary while Mr. Ledger was President, and 66⅔% of 24% of his base salary for Mr. Lunetta. As explained above, Ms. Burkett's annual incentive award also included a Departmental Objective component. For 2016, she earned 100% of 15% of her Controller base salary prorated for 6 months for the achievement of her Departmental Objectives. Mr. Lunetta's annual incentive award also includes a profit sharing element. Under this program, he receives 1.25% of pre-tax earnings generated from the Corporation's manufacturing facility in Varennes, Quebec.

Long-term Incentive Awards

The Corporation's LTI awards are granted through the Corporation's Third Amended and Restated Share Incentive Plan (the "**Share Incentive Plan**") and consist of options granted through a share option plan (the "**Share Option Plan**") and historically, share appreciation rights that were granted through the Corporation's Share Appreciation Rights Plan. In 2013, a Subcommittee was formed to make recommendations to the Compensation, Corporate Governance and Nominating Committee and the Board in respect of LTI awards. In making its recommendation, the Subcommittee considered the Radford Report, the update to the Radford Report in 2013 and the report based on the Canadian Small Cap Companies and determined it was appropriate to use the 2010 recommendations by Radford. In 2016, the Board, on the recommendation of the Compensation, Corporate Governance and Nominating Committee, used the same LTI framework as in 2013 in reviewing executive management LTI awards and granted LTI awards to the NEOs in the form of share options, as described below.

(a) Share Incentive Plan

The Share Incentive Plan consists of the Share Option Plan, a share bonus plan (the "**Share Bonus Plan**") and a share purchase plan (the "**Share Purchase Plan**"). The Board believes that the Share Incentive Plan is a key component of compensation and seeks to integrate compensation incentives with the development and successful execution of strategic and operating plans. The Corporation's Share Incentive Plan is designed to support the achievement of the Corporation's performance objectives and to ensure that the NEOs' interests are aligned with the long-term success of the Corporation. The Share Incentive Plan is administered by the Board based on recommendations of the Compensation, Corporate Governance and Nominating Committee.

As the Share Incentive Plan is a "rolling and reloading plan" (being a plan whereby the maximum number of securities issuable is set as a fixed percentage of the issuer's outstanding securities from time to time and that provides for the replenishment of the number of securities reserved when awards are exercised), the Toronto Stock Exchange (the "**TSX**") requires that it, along with any unallocated options, rights or other entitlements receive shareholder approval at the Corporation's annual meeting every three years. The Share Incentive Plan last received shareholder approval at the Corporation's annual meeting on June 11, 2014. Accordingly, unless securityholder approval is obtained, all unallocated options, rights or other entitlements will be cancelled as of May 11, 2017, the

date of the Meeting, and the Corporation will not be permitted to grant any further entitlements under the Share Incentive Plan; however, previously allocated options or Common Shares will continue to be unaffected. At the Meeting, shareholders of the Corporation will be asked to vote for an ordinary resolution (in substantially the form of resolution set out in Schedule A) affirming, ratifying and approving the Share Incentive Plan and approving all of the unallocated options, the underlying Common Shares and all other Common Shares issuable pursuant to the Share Incentive Plan, as described under the heading “Special Business” below.

The maximum number of Common Shares that may be issued under the Share Incentive Plan is a fixed maximum percentage of 15% of the outstanding Common Shares from time to time (being 1,732,634 Common Shares as of the date of this Circular based on the number of Common Shares currently outstanding); provided that the maximum number of Common Shares that may be issued under the Share Bonus Plan will not exceed 344,615 Common Shares (which is equal to 3% of the number of Common Shares outstanding immediately following the completion of the Reorganization).

Share Option Plan

Under the Share Option Plan, options for the purchase of Common Shares may be granted to officers, employees, consultants and directors of the Corporation and designated affiliates. Options are granted at the discretion of the Board (provided that the aggregate number of Common Shares reserved for issuance to any one person upon the exercise of options shall not exceed 5% of the issued and outstanding Common Shares). To the extent Options have been exercised, terminated or surrendered, new Options may be granted in respect thereof. In determining the number of Common Shares subject to each option, consideration is given to the individual’s recent and potential contribution to the success of the Corporation and its affiliates and the number and timing of options previously granted to the individual. The exercise price per share may not be less than the closing price of the Common Shares trading on the TSX on the last trading day immediately preceding the day the option is granted. Each option has a term of not more than ten years, and, unless otherwise agreed to by the Board, becomes exercisable as to 33.3% of the Common Shares subject to it, on a cumulative basis, at the end of each of the first, second and third years following the date of grant. If a participant (a “**Participant**”) in the Share Option Plan were to die, any option held by such Participant at the date of his or her death shall become immediately exercisable and shall be exercisable by the person to whom the rights of the option shall pass in accordance with the terms of the Participant’s will. No rights under the Share Option Plan and no option awarded pursuant thereto are assignable or transferable by any Participant other than pursuant to a will or by the laws of descent and distribution. If a Participant ceases to be a director, consultant or employee of the Corporation, as the case may be, for any reason (other than death) (such event being a “**Termination**”), except as otherwise provided in an employment contract, consulting agreement or directors’ resolution, such Participant may, but only within 60 days following Termination, exercise his or her options to the extent such Participant was entitled to exercise such options at the date of such Termination.

On the recommendation of the Radford Report, the Compensation, Corporate Governance and Nominating Committee and the Board have determined that generally options granted to the NEOs under the Share Incentive Plan shall have a term of 10 years, shall have an exercise price equal to the closing price of the Common Shares on the TSX on the day immediately prior to the date of the grant and shall vest as follows: one quarter on January 1 of the first year following the grant; one quarter on January 1 of the second year following the grant; one quarter on January 1 of the third year following the grant; and one quarter on January 1 of the fourth year following the grant (notwithstanding the general vesting schedule provided in the Share Option Plan described above). The Board has the discretion and on occasion has varied the vesting period and the exercise price of options granted to NEOs under the Share Incentive Plan.

As part of the Reorganization, each outstanding option to purchase a Nuvo Research common share (an “**Original Nuvo Option**”) as of the Effective Date was exchanged for (a) one option granted by the Corporation to purchase one Common Share (a “**Post-Reorganization Nuvo Option**”); and (b) one option granted by Crescita to purchase one Crescita common share (a “**Crescita Reorganization Option**”). The original exercise price of each Original Nuvo Option exchanged pursuant to the Reorganization was divided between the Post-Reorganization Nuvo Option and the Crescita Reorganization Option acquired by the holder thereof in exchange for such Original Nuvo Option.

Except as noted above and in the Reorganization Circular, the Post-Reorganization Nuvo Options received by a holder of Original Nuvo Options in connection with the Reorganization have substantially the same terms as those of the Original Nuvo Options for which they were exchanged, including their vesting schedule and the term during

which they may be exercised. For purposes of the Share Option Plan, the Post-Reorganization Nuvo Options were deemed to be a continuation of the earlier granted Original Nuvo Option for which they were exchanged, as opposed to a new grant of options. Notwithstanding the requirements of the Share Option Plan, each holder of an Original Nuvo Option at the time of the Reorganization that, in connection with the Reorganization, became a director, officer, employee or consultant of Crescita or one of its designated affiliates shall be permitted, for so long as he or she remains a director, officer, employee or consultant, as applicable, of Crescita or one of its designated affiliates, to hold and exercise his or her Post-Reorganization Nuvo Options received as part of the Reorganization in accordance with their terms as though he or she remained a director, officer, employee or consultant, as applicable, of the Corporation or its designated affiliates eligible to participate in the Share Option Plan. If any such holder at any time is no longer a director, officer, employee or consultant of any of the Corporation, Crescita or any of their respective designated affiliates, he or she shall be treated for purposes of the Share Option Plan as having ceased to be so employed or engaged with the Corporation and its designated affiliates and the rights under his or her Post-Reorganization Nuvo Options shall be affected accordingly.

Share Bonus Plan

The Share Bonus Plan permits Common Shares to be issued by the Corporation as a discretionary bonus to the officers, certain employees and directors of the Corporation, as well as designated affiliates. Persons who perform services for the Corporation are also eligible to receive shares in lieu of cash compensation. The vesting provisions for the Common Shares granted pursuant to the Share Bonus Plan shall be determined by the Board at the time of grant.

Share Purchase Plan

The officers and certain employees of the Corporation or designated affiliates thereof are entitled to contribute up to 10% of their annual base salary to the Share Purchase Plan. The Corporation matches each participant's contribution by issuing Common Shares, having a value equal to the aggregate amount contributed by the participating employee, to such participating employee. Common Shares are issued under the Share Purchase Plan at the weighted average price of the Common Shares on the TSX for the calendar quarter in respect of which such Common Shares are being issued. If a participant ceases to be employed by, or provide service to, the Corporation or its affiliates, any portion of the participant's contribution that has not been used to acquire Common Shares shall be paid to the participant, any portion of the Corporation's contribution that has not been used to acquire Common Shares shall be paid to the Corporation, and any Common Shares held by the Corporation for the benefit of the participant shall be released to the participant in accordance with the terms of the Share Purchase Plan.

(b) Share Appreciation Rights Plan

Following the Reorganization, no additional Share Appreciation Rights may be granted under the Share Appreciation Rights Plan. The Share Appreciation Rights Plan remains in force for the purposes of administering the Post-Reorganization Nuvo SARs (as defined below). The Share Appreciation Rights Plan is administered by the Board (or a committee thereof as delegated by the Board). Except as described below, if a participant in the Share Appreciation Rights Plan ceases to be a director, employee or otherwise engaged by the Corporation (for any reason, including death), there shall be an automatic acceleration of vesting of a pro rata portion of the participant's Share Appreciation Rights based on a formula set out in the Share Appreciation Rights Plan that takes into account the period of time from the grant of the Share Appreciation Rights to the date of termination.

As part of the Reorganization, each outstanding share appreciation right of Nuvo Research (an "**Original Nuvo SAR**") as of the Effective Date was exchanged for (a) one share appreciation right of the Corporation (a "**Post-Reorganization Nuvo SAR**") that entitles the holder thereof to receive, within 30 days following the applicable vesting date, at the option of the holder, either (i) a cash payment equal to the amount, if any, by which the fair market value of one Common Share on the vesting date exceeds the portion of the original grant price of such Original Nuvo SAR allocated to the Post-Reorganization Nuvo SAR, or (ii) Common Shares with a value on the vesting date equal to the cash amount determined under (i); and (b) one share appreciation right of Crescita (a "**Crescita Reorganization SAR**") that entitles the holder thereof to receive, within 30 days following the applicable vesting date, at the option of the holder, either (i) a cash payment equal to the amount, if any, by which the fair market value of one Crescita common share on the vesting date exceeds the portion of the original grant price of such Original Nuvo SAR allocated to the Crescita Reorganization SAR, or (ii) Crescita common shares with a value

on the vesting date equal to the cash amount determined under (i). The original grant price of each outstanding Original Nuvo SAR exchanged pursuant to the Reorganization was divided between the Post-Reorganization Nuvo SAR and the Crescita Reorganization SAR acquired by the holder thereof in exchange for such Original Nuvo SAR.


Except as noted above and in the Reorganization Circular, the Post-Reorganization Nuvo SARs received by a holder of Original Nuvo SARs in connection with the Reorganization have substantially the same terms as those of the Original Nuvo SARs for which they were exchanged, including their vesting schedule. For purposes of the Share Appreciation Rights Plan, the Post-Reorganization Nuvo SARs were deemed to be a continuation of the earlier granted Original Nuvo SARs for which they were exchanged, as opposed to a new grant of share appreciation rights. Notwithstanding the requirements of the Share Appreciation Rights Plan, each holder of an Original Nuvo SAR at the time of the Reorganization that, in connection with the Reorganization, became a director, officer, employee or consultant of Crescita or one of its designated affiliates shall be permitted, for so long as he or she remains a director, officer, employee or consultant, as applicable, of Crescita or one of its designated affiliates, to hold his or her Post-Reorganization Nuvo SARs received as part of the Reorganization in accordance with their terms as though he or she remained a director, officer, employee or consultant, as applicable, of the Corporation or its designated affiliates eligible to participate in the Share Appreciation Rights Plan. If any such Post-Reorganization Nuvo SARs holder at any time is no longer a director, officer, employee or consultant of any of the Corporation, Crescita or any of their respective designated affiliates, he or she shall be treated for purposes of the Share Appreciation Rights Plan as having ceased to be so employed or engaged with the Corporation and its designated affiliates and the rights under his or her Post-Reorganization Nuvo SARs shall be affected accordingly.

(c) Deferred Share Unit Employee Plan (“DSU Employee Plan”)

Prior to the Reorganization, the Corporation had the DSU Employee Plan, a share-based compensation plan for employees. As part of the Reorganization, all of the DSUs outstanding immediately prior to the effective time of the Reorganization were ultimately exchanged for a number of Common Shares equal to the number of DSUs so exchanged (net of applicable withholdings). The DSU Employee Plan was terminated as of the Effective Date and no additional DSUs may be granted thereunder.

Performance Graph

The following graph compares the yearly percentage change in the cumulative total shareholder return on the Common Shares from January 1, 2011 to December 31, 2016, with the cumulative total return of the S&P/TSX Composite Index during the same period, assuming a \$100 initial investment (and the re-investment of any dividends).



Year	2011	2012	2013	2014	2015	2016
	\$	\$	\$	\$	\$	\$
S&P/TSX Composite Index	100	104	114	122	109	128
S&P/TSX Capped Health Care Index	100	111	155	184	225	125
NRI	100	120	66	215	160	222

The trend shown by the above performance graph demonstrates an increase in cumulative shareholder return from 2011 to 2016. For the purpose of this graph, it has been assumed that, upon completion of the Reorganization, the Crescita shares received by Nuvo shareholders were sold on the first day of trading and that the proceeds were reinvested in shares of Nuvo on that day. The value of the Crescita shares were determined using the “Butterfly Proportion” allocated to Crescita shares as described in the Reorganization Circular.

During this 5-year period, base salary compensation to the NEOs was frozen in 2013 and 2014. In 2015, the Corporation granted modest base salary increases based on changes in inflation. In 2016, base salary compensation was frozen, other than to account for employment changes of certain employees and a modest increase to account for inflation for Mr. Lunetta. See the section entitled “*Compensation Philosophy – Base Salary*” of this Circular. While a portion of the compensation received by NEOs is subject to the performance of the Common Shares on the TSX, including with respect to each NEO’s participation in the Share Incentive Plan and Share Appreciation Rights Plan, the determination of NEO compensation is not solely determined with reference to total shareholder return and is subject to a number of factors (as described in more detail in this Circular). Accordingly, the total compensation of each NEO is not directly correlated to the performance of the Common Shares on the TSX over the past five years. In the life sciences industry, and particularly in drug development, shareholder returns are typically created by the achievement of certain preclinical, clinical, regulatory approval and commercialization milestones. The Corporation’s most significant milestones in its history occurred on November 5, 2009, when the U.S. Food and Drug Administration (the “**FDA**”) advised the Corporation it approved the New Drug Application for the sale and marketing of Pennsaid[®] in the United States and on June 15, 2009, when the Corporation entered into a U.S. License and Development Agreement with Mallinckrodt, Inc., a subsidiary of Covidien, for Pennsaid[®] and Pennsaid[®] 2%. Another significant milestone in the Corporation’s history occurred in 2012, when the Corporation received approval of Plialis[®] by the FDA and by the German Federal Institute for Drugs and Medical Devices (BfArM). In

Europe, marketing licenses have been issued in all 16 countries which are listed in the European Marketing Application for Pliaglis[®]. The Corporation licensed worldwide marketing rights for Pliaglis[®] to Galderma Pharma S.A. (“Galderma”), a global pharmaceutical company specialized in dermatology. Galderma launched Pliaglis[®] in the United States in March 2013 and in Europe in April 2013. In 2015, the Corporation required the Canadian, U.S. and Mexican rights to Pliaglis[®] from Galderma. Pliaglis transferred to Crescita pursuant to the Reorganization. Further significant milestones in the Corporation’s history occurred in 2014, when the FDA approved the New Drug Application for the sale and marketing of Pennsaid[®] 2% in the United States in January 2014; the Company settled its litigation with Mallinckrodt, Inc., the Company’s U.S. marketing partner for Pennsaid[®] and Pennsaid[®] 2%, in September 2014; and the Company sold the U.S. Rights to Pennsaid[®] 2% to Horizon Pharma plc in October 2014. Events in 2016 that influenced the Company’s share price include the results of the Company’s Phase 2 clinical trials to investigate the safety and efficacy of WF10 in patients with refractory allergic rhinitis and Pennsaid[®] 2% in patients with grade I or II ankle sprains. WF10 transferred to Crescita pursuant to the Reorganization.

Hedging of Equity-Based Compensation

While the Corporation does not have a specific policy against it, to the Corporation’s knowledge, NEOs and directors do not purchase financial instruments designed to hedge or offset a decrease in the market value of equity securities of the Corporation granted as compensation or held, directly or indirectly, by the NEO or director.

Summary Compensation Table

The following table sets forth the annual compensation, including total compensation, for the financial year ended December 31, 2016 for each of the NEOs of the Corporation.

Summary Compensation Table

Name and principal position	Year	Salary (\$)	Share-based awards (\$)	Option-based award (\$)	Non-equity incentive plan compensation (\$)		All other compensation (\$)	Total compensation (\$)
					Annual incentive plans ⁽²⁾	Long-term incentive plans		
Daniel Chicoine Chairman and Former Co-CEO ⁽⁹⁾	2016	71,753	Nil	Nil	Nil	Nil	2,885 ⁽³⁾	74,638
	2015	405,563	Nil	222,859	60,801 ⁽⁴⁾	Nil	15,000 ⁽³⁾	704,223
	2014	190,897 ⁽⁸⁾	195,353 ⁽⁸⁾	187,248	207,609 ⁽⁴⁾	Nil	15,000 ⁽³⁾	796,107
John London CEO ⁽¹⁰⁾	2016	405,563	Nil	280,951 ⁽¹⁾	135,052 ⁽⁴⁾	Nil	15,000 ⁽³⁾	836,566
	2015	405,563	Nil	222,859	60,801 ⁽⁴⁾	Nil	15,000 ⁽³⁾	704,223
	2014	190,897 ⁽⁸⁾	195,353 ⁽⁸⁾	187,248	207,609 ⁽⁴⁾	Nil	15,000 ⁽³⁾	796,107
Stephen Lemieux Former Vice President and CFO ⁽¹¹⁾	2016	216,124	Nil	79,219 ⁽¹⁾	Nil	Nil	9,102 ⁽³⁾	304,445
	2015	267,800	Nil	125,675	32,125 ⁽⁴⁾	Nil	9,600 ⁽³⁾	435,200
	2014	260,000	Nil	105,591	111,800 ⁽⁴⁾	Nil	9,600 ⁽³⁾	486,991
Mary-Jane Burkett Vice President and CFO ⁽¹²⁾	2016	157,692	Nil	16,851 ⁽¹⁾	31,230 ⁽⁵⁾	Nil	4,708 ⁽³⁾	210,481
	2015	114,423	Nil	Nil	21,740 ⁽⁵⁾	Nil	Nil	136,163
	2014	91,699	Nil	Nil	5,502 ⁽⁵⁾	Nil	Nil	97,201
Henrich Guntermann Former President, Europe and Immunology Group ⁽¹³⁾	2016	63,858	Nil	Nil	Nil	Nil	55,365 ⁽¹⁵⁾	119,223
	2015	360,938	Nil	117,561	46,406 ⁽⁶⁾	Nil	15,000 ⁽³⁾	539,905
	2014	343,750	Nil	98,775	112,578 ⁽⁶⁾	Nil	15,000 ⁽³⁾	570,103
Jesse Ledger President ⁽¹⁴⁾	2016	170,231	Nil	82,994 ⁽¹⁾	36,333 ⁽⁴⁾	Nil	10,800 ⁽³⁾	300,358
	2015	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	2014	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Name and principal position	Year	Salary (\$)	Share-based awards (\$)	Option-based award (\$)	Non-equity incentive plan compensation (\$)		All other compensation (\$)	Total compensation (\$)
					Annual incentive plans ⁽²⁾	Long-term incentive plans		
Calogero Lunetta Vice President, Manufacturing	2016	129,189	Nil	33,702 ⁽¹⁾	202,280 ⁽⁷⁾	Nil	7,200 ⁽³⁾	372,371
	2015	126,803	Nil	Nil	152,568 ⁽⁷⁾	Nil	N/A	279,371
	2014	123,885	Nil	Nil	53,630 ⁽⁷⁾	Nil	N/A	177,505

Notes:

- (1) The values of stock options awarded in 2016 are the estimated fair values on the date of grant calculated using the Black-Scholes option pricing model, which appears to be standard among public companies, pursuant to International Financial Reporting Standard 2, with the following assumptions:

	Options
Grant Date	March 23, 2016
Risk-free interest rate	0.49% - 0.53%
Dividend Yield	Nil
Expected volatility of share price	71% - 75%
Expected life	2 – 5 years
Forfeiture rate	7%
Common share price	\$5.42
Fair value of option	\$2.10 – \$3.27

The stock options granted in 2016 vest 25% on each of January 1, 2017, 2018, 2019 and 2020. As of the date hereof, the stock options issued are not “in-the-money”.

- (2) Represents a bonus which was approved for payment relating to the respective calendar year performance.
- (3) Represents payment received as an annual car allowance.
- (4) The annual incentive award was fully based on achievement of the Corporate Objectives established at the beginning of the year and as assessed by the Board.
- (5) For Ms. Burkett in 2016, a target bonus range of 15% was set on Departmental Objectives related to her position as Corporate Controller and her base salary prorated for six months as Corporate Controller, and 30% was set using the Corporate Objectives and her base salary prorated for six months as Vice President and CFO. For 2015 and 2014, prior to her appointment as Vice President and CFO of the Corporation, Ms. Burkett’s annual incentive award was fully based on achievement of Departmental Objectives.
- (6) 50% of the annual incentive award was based on achievement of the Corporate Objectives and 50% of the annual incentive award was based on achievement of the Divisional Objectives.
- (7) For 2016, Mr. Lunetta’s annual incentive award was based on achievement of Corporate Objectives (\$20,787) and as described herein a profit sharing element (\$181,493). For 2015 and 2014, Mr. Lunetta’s annual incentive award was based on achievement of Divisional Objectives and as described herein a profit sharing element.
- (8) Effective July 1, 2013 until December 31, 2014, Mr. Chicoine and Mr. London each had the right to receive 50% of his base salary in cash and 50% of his base salary in the form of DSUs. Mr. Chicoine and Mr. London were required to elect prior to the beginning of each quarter as to what percentage of their base salary (up to 50%), they chose to receive in DSUs. The elected percentage of DSUs for the quarter were paid at the end of such quarter based on an issue price equal to the 5-day volume weighted average price as of the last trading day of such quarter.
- (9) As of March 1, 2016, Mr. Chicoine resigned as Co-CEO and currently holds the position of Chairman of the Corporation.
- (10) On March 1, 2016, Mr. London was appointed President and CEO and on November 15, 2016, Mr. London resigned as President. He currently holds the position of CEO.
- (11) Effective September 9, 2016, Mr. Lemieux resigned as Vice President and CFO.
- (12) Effective September 12, 2016, Ms. Burkett was appointed Vice President and CFO. Prior to this appointment, she was employed by the Corporation as Controller.
- (13) Effective March 1, 2016, Dr. Guntermann resigned as President, Europe and Immunology Group.
- (14) Mr. Ledger was hired by the Corporation on April 1, 2016 as Vice President, Business Development and was appointed President on November 15, 2016.
- (15) Represents payments received for consulting services related to overseeing the Pennsaid 2% clinical trial in Germany (\$52,480) and for a car allowance (\$2,885).

Incentive Plan Awards

Outstanding Share-based Awards and Option-based Awards

The following table indicates for each of the NEOs all awards outstanding at the end of the 2016 financial year.

Name	Option-based awards					Share-based awards		
	Number of securities underlying unexercised options / SARs (#)	Option / SAR exercise price (\$)	Option / SAR grant date	Option / SAR expiration date	Value of unexercised in-the-money options or SARs ⁽⁷⁾ (\$)	Number of shares or units of shares that have not vested (#)	Market or payout value of share awards that have not vested (\$)	Market or payout value of vested share awards not paid out (\$)
Daniel Chicoine Chairman and Former Co-CEO ⁽¹⁾	51,579	5.63	Jan 7, 2015	Jan 1, 2019	1,083	Nil	Nil	Nil
	59,158	2.65	May 6, 2014	May 6, 2024	177,474			
	44,368	2.65	Apr 4, 2014	Jan 1, 2018	133,091			
	42,452	1.45	Oct 30, 2013	Jan 1, 2017	178,454			
	44,368	5.08	Mar 29, 2012	Mar 29, 2022	25,290			
	8,812	4.32	Aug 16, 2011	Aug 16, 2021	11,720			
	16,608	11.18	June 16, 2010	June 16, 2020	Nil			
	53,846	6.86	Nov 7, 2007	Nov 7, 2017	Nil			
John London CEO ⁽²⁾	102,537	5.42	Mar 23, 2016	Mar 23, 2026	23,584	Nil	Nil	Nil
	51,579	5.63	Jan 7, 2015	Jan 1, 2019	1,083			
	59,158	2.65	May 6, 2014	May 6, 2024	177,474			
	44,368	2.65	Apr 4, 2014	Jan 1, 2018	133,091			
	42,452	1.45	Oct 30, 2013	Jan 1, 2017	178,454			
	44,368	5.08	Mar 29, 2012	Mar 29, 2022	25,290			
	8,812	4.32	Aug 16, 2011	Aug 16, 2021	11,720			
	16,608	11.18	June 16, 2010	June 16, 2020	Nil			
	53,846	6.86	Nov 7, 2007	Nov 7, 2017	Nil			
Stephen Lemieux Former Vice President and CFO ⁽³⁾	Nil	Nil	Nil	Nil	Nil	Nil	Nil	Nil

Name	Option-based awards					Share-based awards		
	Number of securities underlying unexercised options / SARs (#)	Option / SAR exercise price (\$)	Option / SAR grant date	Option / SAR expiration date	Value of unexercised in-the-money options or SARs ⁽⁷⁾ (\$)	Number of shares or units of shares that have not vested (#)	Market or payout value of share awards that have not vested (\$)	Market or payout value of vested share awards not paid out (\$)
Mary-Jane Burkett Vice President and CFO ⁽⁴⁾	6,150	5.42	Mar 23, 2016	Mar 23, 2026	1,415	Nil	Nil	Nil
Henrich Guntermann Former President, Europe and Immunology Group ⁽⁵⁾	27,208	5.63	Jan 7, 2015	Jan 1, 2019	571	Nil	Nil	Nil
	31,206	2.65	May 6, 2014	May 6, 2024	93,618			
	23,405	2.65	Apr 4, 2014	Jan 1, 2018	70,208			
	21,983	1.45	Oct 30, 2013	Jan 1, 2017	92,409			
	23,404	5.08	Mar 29, 2012	Mar 29, 2022	13,340			
	4,644	4.32	Aug 16, 2011	Aug 16, 2021	6,177			
	8,760	11.18	June 16, 2010	June 16, 2020	Nil			
	53,846	6.86	Nov 7, 2007	Nov 7, 2017	Nil			
Jesse Ledger President ⁽⁶⁾	33,825	5.42	Mar 23, 2016	Mar 23, 2026	7,780	Nil	Nil	Nil
Calogero Lunetta VP, Manufacturing	12,300	5.42	Mar 23, 2016	Mar 23, 2026	2,829	Nil	Nil	Nil
	15,000	1.53	Dec 20, 2013	Dec 20, 2023	61,800			
	1,536	6.35	May 6, 2008	May 6, 2018	Nil			

Notes:

- (1) As of March 1, 2016, Mr. Chicoine resigned as Co-CEO and currently holds the position of Chairman of the Corporation.
- (2) On March 1, 2016, Mr. London was appointed President and CEO and on November 15, 2016, Mr. London resigned as President. He currently holds the position of CEO.
- (3) Effective September 9, 2016, Mr. Lemieux resigned as Vice President and CFO.
- (4) Effective September 12, 2016, Ms. Burkett was appointed Vice President and CFO.
- (5) Dr. Guntermann resigned as President, Europe and Immunology Group effective March 1, 2016.
- (6) Mr. Ledger was hired by the Corporation on April 1, 2016 as Vice President, Business Development and was appointed President on November 15, 2016.
- (7) Value of unexercised in-the-money options and SARs determined at December 31, 2016.

Incentive-Plan Awards – Value Vested or Earned during the Year

The following table indicates for each of the NEOs the value on vesting of all awards (had they been exercised on the vesting date) during the 2016 financial year.

Name	Option-based awards – Value during the year on vesting (\$)	Share-based awards – Value during the year on vesting (\$)	Non-equity incentive plan compensation – Value earned during the year⁽³⁾ (\$)
Daniel Chicoine	55,165	820,087 ^(1,2)	Nil
John London	55,165	820,087 ^(1,2)	Nil
Stephen Lemieux	31,108	103,205 ⁽¹⁾	Nil
Mary-Jane Burkett	Nil	Nil	Nil
Jesse Ledger	Nil	Nil	Nil
Henrich Guntermann	29,100	95,161 ⁽¹⁾	Nil
Calogero Lunetta	Nil	Nil	Nil

Notes:

- (1) Includes amounts paid by the Corporation for the settlement of Share Appreciation Rights that vested January 1, 2016.
- (2) Upon execution of the Reorganization on March 1, 2016, all outstanding DSUs for employees were settled in shares of Nuvo net of the cash tax obligation that was payable by Nuvo.
- (3) This information appears in the table on pages 18-19.

	Number of securities to be issued upon the exercise of outstanding options (000s)	Weighted-average exercise price of outstanding options	Number of securities remaining available for future issuance under the equity compensation plan (excluding securities reflected in Column (a))⁽¹⁾ (000s)
	(a)		
Equity compensation plans approved by Shareholders	849	\$5.01	883
Equity compensation plans not approved by Shareholders	Nil	Nil	Nil

Notes:

- (1) The maximum number of Common Shares that may be issued under the Share Incentive Plan is a fixed maximum percentage of 15% of the Corporation's outstanding Common Shares from time-to-time. Prior to the completion of the Reorganization, the Common Shares permitted be issued under the plan were allocated to the three sub-plans as follows: 10% to the Share Option Plan, 3% to the Share Purchase Plan and 2% to the Share Bonus Plan. As described above, in connection with the Reorganization, the Share Incentive Plan was amended as of the Effective Date to provide that the aggregate maximum of Common Shares made available for, and reserved for issuance under, the Share Incentive Plan would remain unchanged at 15% of the total number of Common Shares outstanding from time to time, but the allocation of such maximum percentage among the Share Option Plan, Share Bonus Plan and Share Purchase Plan will be determined by the Board (or a committee thereof) from time to time (provided that the maximum number of Common Shares that may be issued under the Share Bonus Plan will not exceed a fixed number of Common Shares equal to 3% of the number of Common Shares outstanding immediately following the completion of the Reorganization). As the Share Incentive Plan is a "rolling and reloading plan", the TSX requires that it, along with any unallocated options, rights or other entitlements receive shareholder approval at the Corporation's annual meeting every three years. At the Meeting, shareholders of the Corporation will be asked to vote for an ordinary resolution (in substantially the form of resolution set out in Schedule A) affirming, ratifying and approving the Share Incentive Plan and approving all of the unallocated options, the underlying

Common Shares, and all other Common Shares issuable pursuant to the Share Incentive Plan, as described under the heading “Special Business” below.

Employment Agreements

Following the election of the Corporation’s Board at the annual shareholders meeting on September 21, 2004, the Board appointed a new President and Chief Executive Officer, Dr. Henrich Guntermann. That appointment was made on September 22, 2004. In November 2004, directors Daniel Chicoine and John London officially joined the Corporation’s management team as Chairman and Vice Chairman, respectively.

On December 1, 2009, subsequent to approval of the Pennsaid® NDA by the U.S. FDA, the Board reorganized the Corporation’s structure to better position the Corporation for future growth by naming presidents for each business segment. Dr. Henrich Guntermann, formerly President & CEO of the Corporation, was appointed President, Europe and Immunology Group. To fill the CEO vacancy created by the appointment of Dr. Guntermann to his new role, Daniel Chicoine, in addition to his role as Chairman of the Board was appointed Co-Chief Executive Officer and John London was appointed President and Co-Chief Executive Officer.

On December 17, 2004, the Board, on recommendation of the Compensation, Corporate Governance and Nominating Committee (then the Compensation and Corporate Governance Committee), approved terms of employment that were incorporated into employment agreements dated April 29, 2005 between the Corporation and each of Messrs. Chicoine and London. These agreements were amended with approval of the Compensation, Corporate Governance and Nominating Committee on June 17, 2010 to reflect the recommendations by Radford. The employment agreement for Mr. London was stated to be effective December 1, 2004. The employment agreement for Mr. Chicoine was stated to be effective January 1, 2005. Mr. Chicoine resigned from the Corporation as the Corporation’s Co-CEO effective March 1, 2016. Mr. London’s position changed from President and Co-CEO to President and CEO effective March 1, 2016 and changed to CEO effective November 15, 2016, when Mr. Jesse Ledger was appointed President.

Under the terms of his employment agreement, if Mr. London is terminated for cause, he will not be entitled to any payment or compensation from the Corporation. If he is terminated without cause, he will be entitled to receive a retiring allowance equal to twelve months of his base salary and automobile allowance payable either in a lump sum or in twelve equal monthly installments commencing within thirty days after the day of termination. As at December 31, 2016, the payout would have been \$420,563. In the event of a change of control of the Corporation (defined as (i) an acquisition of 30% or more of the Common Shares by any person or group together with a change of 30% or more of the members of the Board within 12 months thereafter or (ii) a de facto change of control), for a period of twelve months thereafter, any termination of his employment by the Corporation for any reason, shall entitle Mr. London to receive a lump sum payment equal to two times the amount that they would have received if his employment was terminated without cause. Mr. London would have been entitled to receive a lump sum payment of \$841,126 if his employment was terminated as of December 31, 2016 following a change of control of the Corporation within the preceding 12-month period. In addition, upon such change of control, he would have the right, for a period of twelve months thereafter, to terminate his employment by providing the Corporation with written notice of termination, and upon doing so he will be entitled to a payment of the amount set out in the preceding sentence. Upon a change of control, any options, rights, warrants or other entitlements for the purchase or acquisition of shares in the Corporation that are not then exercisable shall be fully vested and accelerated so that they become immediately exercisable for 180 days. As of December 31, 2016, Mr. London received an annual base salary of \$405,563 and an annual car allowance of \$15,000. As mentioned above, Mr. Chicoine resigned from the Corporation as the Corporation’s Co-CEO effective March 1, 2016 and from January 1, 2016 to his resignation date, he received a base salary of \$405,563 and an annual car allowance of \$15,000 in 2016 that were prorated to his date of resignation.

On December 17, 2004, the Board, on recommendation of the Compensation, Corporate Governance and Nominating Committee (then the Compensation and Corporate Governance Committee), approved terms of employment that were incorporated into an employment agreement dated April 29, 2005 between the Corporation and Dr. Guntermann and was stated to be effective December 1, 2004. This agreement was amended with approval of the Compensation, Corporate Governance and Nominating Committee on June 17, 2010 to reflect the recommendations by Radford. Dr. Guntermann voluntarily resigned from the Corporation as of March 1, 2016. Under the terms of his agreement, if Dr. Guntermann was terminated for cause, he would not be entitled to any

payment or compensation from the Corporation. As his employment was terminated without cause, he was entitled to receive a retiring allowance equal to twelve months of his base salary and automobile allowance payable either in a lump sum or in twelve equal monthly installments commencing within thirty days after the day of termination. As at December 31, 2016, the payout would have been \$375,938. In the event of a change of control of the Corporation (as defined above), for a period of twelve months thereafter, any termination of his employment by the Corporation for any reason, would have entitled Dr. Guntermann to receive a lump sum payment equal to two times the amount that he would have received if his employment was terminated without cause. Dr. Guntermann would have been entitled to receive a lump sum payment of \$751,875 if his employment was terminated following a change of control of the Corporation within the preceding 12-month period. In addition, upon such change of control, Dr. Guntermann would have had the right, for a period of twelve months thereafter, to terminate his employment by providing the Corporation with written notice of termination, and upon doing so he would have been entitled to a payment of the amount set out in the preceding sentence. Upon a change of control, any options, rights, warrants or other entitlements for the purchase or acquisition of shares in the Corporation that were not then exercisable shall be fully vested and accelerated so that they become immediately exercisable for 180 days. As mentioned above, Dr. Guntermann resigned as of March 1, 2016 and from January 1, 2016 to his resignation date, he received a base salary of \$360,938 and an annual car allowance of \$15,000 in 2016 that were prorated to his date of resignation. On July 1, 2016, Dr. Guntermann entered into a consulting agreement with the Corporation to assist with its activities in Europe, including the Phase 3 clinical trial being conducted in Germany for Pennsaid 2%.

The Corporation has also entered into employment agreements with its other NEOs including: Mr. Stephen Lemieux, the Corporation's former Vice President and Chief Financial Officer, Ms. Mary-Jane Burkett, the Corporation's Vice President and Chief Financial Officer, Mr. Jesse Ledger, the Corporation's President and Mr. Lunetta, the Corporation's Vice President, Manufacturing. Ms. Burkett, Mr. Ledger and Mr. Lunetta are currently employed by the Corporation.

Mr. Lemieux resigned from the Corporation as of September 9, 2016. Prior to his resignation and following completion of the Reorganization, Mr. Lemieux continued to be employed as the Vice President and CFO of the Corporation in accordance with the existing terms of his employment arrangements. Pursuant to an agreement entered into between Crescita and the Corporation (the "**Transition Services Agreement**"), the Corporation agreed to make Mr. Lemieux's services available to Crescita to act as Crescita's Vice President and CFO. Crescita agreed to reimburse the Corporation for a portion of Mr. Lemieux's aggregate compensation based on the proportion of Mr. Lemieux's time that is dedicated to services provided to Crescita. These transition services terminated upon Mr. Lemieux's resignation from the Corporation. Under the terms of Mr. Lemieux's employment agreement, if terminated for cause, he would not have been entitled to any payment or compensation. If the Corporation terminated Mr. Lemieux without cause, he would have been entitled to receive a retiring allowance equal to twelve months of his base salary and an automobile allowance payable either in a lump sum or in twelve equal monthly installments commencing within thirty days after the day of termination. The retiring payout for Mr. Lemieux would have been \$282,200. Mr. Lemieux did not receive a retiring allowance. In the event of a change of control of the Corporation (as defined above), for a period of twelve months thereafter, any termination of his employment by the Corporation for any reason, would have entitled Mr. Lemieux to receive a lump sum payment equal to two times the amount that he would have received if terminated without cause. Mr. Lemieux would have been entitled to receive a lump sum payment of \$564,400 if his employment was terminated following a change of control of the Corporation within the preceding 12-month period. In addition, upon such change of control, he would have the right, for a period of twelve months thereafter, to terminate his employment by providing the Corporation with written notice of termination, and upon doing so he would have been entitled to payment of the amount set out in the preceding sentence. Upon a change of control, any options, rights, warrants or other entitlements for the purchase or acquisition of shares in the Corporation that are not then exercisable would have been fully vested and accelerated so that they become immediately exercisable for 180 days. As mentioned above, Mr. Lemieux resigned as of September 9, 2016, and from January 1, 2016 to his resignation date, he received a base salary of \$267,800 and an annual car allowance of \$14,400 in 2016 that were prorated to his date of resignation.

Under the terms of Ms. Burkett's employment agreement, if terminated for cause, she will not be entitled to any payment or compensation. If the Corporation terminates Ms. Burkett without cause, she will be entitled to receive a retiring allowance equal to twelve months of her base salary and an automobile allowance payable either in a lump sum or in twelve equal monthly installments commencing within thirty days after the day of termination. As at December 31, 2016, the payout to Ms. Burkett would have been \$214,400. In the event of a change of control of the Corporation (as defined above), for a period of twelve months thereafter, any termination of her employment by the

Corporation for any reason, shall entitle Ms. Burkett to receive a lump sum payment equal to two times the amount that she would have received if terminated without cause. Ms. Burkett would have been entitled to receive a lump sum payment of \$428,800 if her employment was terminated as of December 31, 2016 following a change of control of the Corporation within the preceding 12-month period. In addition, upon such change of control, she will have the right, during the period of six months to the date of the change of control to twelve months thereafter, to terminate her employment by providing the Corporation with written notice of termination, and upon doing so she will be entitled to payment of the amount set out in the preceding sentence. Upon a change of control, any options, rights, warrants or other entitlements for the purchase or acquisition of shares in the Corporation that are not then exercisable shall be fully vested and accelerated so that they become immediately exercisable for 180 days. As of December 31, 2016, Ms. Burkett received an annual salary of \$200,000 and an annual car allowance of \$14,400.

Under the terms of Mr. Ledger's employment agreement, if terminated for cause, he will not be entitled to any payment or compensation. If the Corporation terminates Mr. Ledger's without cause, he will be entitled to receive a retiring allowance equal to twelve months of his base salary and an automobile allowance payable either in a lump sum or in twelve equal monthly installments commencing within thirty days after the day of termination. As at December 31, 2016, the payout to Mr. Ledger would have been \$274,400. In the event of a change of control of the Corporation (as defined above), for a period of twelve months thereafter, any termination of his employment by the Corporation for any reason, shall entitle Mr. Ledger to receive a lump sum payment equal to two times the amount that he would have received if terminated without cause. Mr. Ledger would have been entitled to receive a lump sum payment of \$548,800 if his employment was terminated as of December 31, 2016 following a change of control of the Corporation within the preceding 12-month period. In addition, upon such change of control, he will have the right, for a period of twelve months thereafter, to terminate his employment by providing the Corporation with written notice of termination, and upon doing so he will be entitled to payment of the amount set out in the preceding sentence. Upon a change of control, any options, rights, warrants or other entitlements for the purchase or acquisition of shares in the Corporation that are not then exercisable shall be fully vested and accelerated so that they become immediately exercisable for 180 days. As of December 31, 2016, Mr. Ledger received an annual salary of \$260,000 and an annual car allowance of \$14,400.

Under the terms of Mr. Lunetta's employment agreement, if terminated for cause, he will not be entitled to any payment or compensation. If the Corporation terminates Mr. Lunetta without cause, he will be entitled to receive severance as provided by statutory and/or common law. In the event of a change of control of the Corporation's manufacturing facility, which is defined as a sale of all or substantially all the assets of the Corporation's manufacturing facility in Varennes, Quebec; any merger, consolidation or acquisition of the Corporation's manufacturing facility with, by or into another corporation, entity or person; or any change in the ownership of more than 50% of the Corporation's manufacturing facility in one or more related transactions, shall entitle Mr. Lunetta to receive an immediate lump sum payment equal to \$100,000. As of December 31, 2016, Mr. Lunetta received an annual salary of \$130,050 and an annual car allowance of \$7,200.

Compensation of Directors

In 2011, the Compensation, Corporate Governance and Nominating Committee and Board established a compensation plan for non-employee independent directors of the Corporation based on expert advice received from Radford. The compensation plan is structured to take into account the best interests of the Corporation and to ensure that the directors' compensation appropriately reflects their responsibilities and includes short-term and long-term compensation elements. As of July 1, 2011, the compensation structure changed to include cash compensation, share-based awards and stock options. The per meeting attendance fees were removed from the compensation plan in favour of a structure that pays set annual retainers. Directors who also act as NEOs of the Corporation are not given additional compensation for their role as directors of the Corporation.

Cash Compensation

As of July 1, 2011, the following cash compensation was set for non-employee independent directors: \$35,000 annual Board retainer; \$10,000 Lead Director additional retainer; \$16,000 audit committee chair retainer; \$12,000 compensation, corporate governance and nominating committee chair retainer; \$8,000 audit committee member; and \$6,000 compensation, corporate governance and nominating committee member. Directors are reimbursed for expenses incurred in attending Board and committee meetings or otherwise in the performance of their duties. Directors are no longer paid fees based on the number of meetings attended.

Deferred Share Unit Plan (“DSU Plan”)

On January 1, 2009, the Corporation established the DSU Plan, a share-based compensation plan for non-employee directors. Under this DSU Plan, non-employee directors can be allotted and can elect to receive a portion of their annual retainers and other Board-related compensation in the form of DSUs. One DSU has a cash value equal to the market price of one Common Share and the number of DSUs issued to a director’s DSU account for any payment is determined using the five-day volume weighted average price of the Common Shares immediately preceding the payment date. Upon issuance, the fair value of the DSUs is recorded as compensation expense and the DSU Accrual is established. At all subsequent reporting dates, the DSU Accrual is adjusted to the market value of the underlying Common Shares and the adjustment is recorded as compensation cost. Within a specified time after retirement, non-employee directors receive a cash payment equal to the market value of their DSUs.

As part of the Reorganization, all of the DSUs outstanding immediately prior to the effective time of the Reorganization were exchanged for a number of Nuvo Research common shares equal to the number of DSUs so exchanged. The number of Nuvo Research common shares issued to each holder of DSUs in exchange for such holders’ DSUs was reduced by a number of Nuvo Research common shares with a value equal to the amount that the Corporation was required to withhold under the *Income Tax Act* (Canada) in respect of the Nuvo Research common shares to be issued to such holder. The Nuvo Research common shares received in exchange for DSUs (net of any withholdings as described above) ultimately were exchanged in connection with the Reorganization for Common Shares and Crescita common shares. Holders of DSUs who received Nuvo Research common shares in exchange for their DSUs in connection with the Reorganization have agreed not to sell such Nuvo Research common shares for a period of one year from the Effective Date.

The DSU Plan was terminated as of the Effective Date and no additional DSUs may be granted thereunder.

Independent Directors’ Compensation for the Fiscal Year Ended December 31, 2016

Name	External Directors’ Fees (\$)	Share-based awards ⁽¹⁾ (\$)	Option-based awards (\$)	Non-equity incentive plan compensation		All other compensation (\$)	Total compensation (\$)
				Annual incentive plans	Long-term incentive plans		
David Copeland	53,000	20,000	Nil	Nil	Nil	Nil	73,000
Anthony Dobranowski	49,000	20,000	Nil	Nil	Nil	Nil	69,000
Klaus von Lindeiner	8,167	20,000	Nil	Nil	Nil	Nil	28,167
Jacques Messier	47,000	20,000	Nil	Nil	Nil	Nil	67,000
Theodore H. Stanley	6,833	20,000	Nil	Nil	Nil	Nil	26,833
Samira Sakhia ⁽²⁾	57,000	20,000	23,631	Nil	Nil	Nil	100,631

Notes:

- (1) This includes an annual grant of DSUs valued at \$20,000.
- (2) Ms. Sakhia was appointed to the Board of Directors on October 29, 2015. She received her initial grant of stock options March 23, 2016. The values of stock options awarded in 2016 are the estimated fair values on the date of grant calculated using the Black-Scholes option pricing model, which appears to be standard among public companies, pursuant to International Financial Reporting Standard 2. The assumptions are outlined on page 19.

Incentive Plan Awards

Outstanding Share-based Awards and Option-based Awards

The following table indicates for each of the directors all awards outstanding at the end of the 2016 financial year.

Name	Option-based awards					Share-based awards ⁽¹⁾		
	Number of securities underlying unexercised options (#)	Option exercise price (\$)	Option grant date	Option expiration date	Value of unexercised in-the-money options (\$)	Number of shares or units of shares that have not vested (#)	Market or payout value of share awards that have not vested (\$)	Market or payout value of vested share awards not paid out (\$)
David Copeland	6,153	\$4.32	Aug 16, 2011	Aug 16, 2021	8,183	Nil	Nil	Nil
	2,688	\$6.35	May 6, 2008	May 6, 2018	Nil			
	1,050	\$12.70	May 4, 2007	May 4, 2017	Nil			
Anthony Dobranowski	6,153	\$4.32	Aug 16, 2011	Aug 16, 2021	8,183	Nil	Nil	Nil
	2,688	\$6.35	May 6, 2008	May 6, 2018	Nil			
	1,050	\$12.70	May 4, 2007	May 4, 2017	Nil			
Klaus von Lindeiner ⁽²⁾	6,153	\$4.32	Aug 16, 2011	Aug 16, 2021	8,183	Nil	Nil	Nil
	2,688	\$6.35	May 6, 2008	May 6, 2018	Nil			
	1,050	\$12.70	May 4, 2007	May 4, 2017	Nil			
Jacques Messier	6,153	\$4.32	Aug 16, 2011	Aug 16, 2021	8,183	Nil	Nil	Nil
	2,688	\$6.35	May 6, 2008	May 6, 2018	Nil			
	1,050	\$12.70	May 4, 2007	May 4, 2017	Nil			
Theodore H. Stanley ⁽²⁾	9,228	\$4.32	Aug 16, 2011	Aug 16, 2021	12,273	Nil	Nil	Nil
Samira Sakhia	9,231	\$5.42	Mar 23, 2016	Mar 23, 2026	2,123	Nil	Nil	Nil

Notes:

(1) Value of unexercised in-the-money options determined at December 31, 2016.

(2) Drs. von Lindeiner and Stanley resigned from the Corporation's Board of Directors on March 1, 2016.

Incentive-Plan Awards – Value Vested or Earned during the Year

The following table indicates for each of the directors the value on vesting of all awards (had they been exercised on the vesting date) during the 2016 financial year.

Name	Option-based awards – Value during the year on vesting (\$)	Share-based awards – Value during the year on vesting (\$)⁽¹⁾	Non-equity incentive plan compensation – Value earned during the year (\$)
David Copeland	Nil	345,254	Nil
Anthony Dobranowski	Nil	316,225	Nil
Klaus von Lindeiner	Nil	305,649	Nil
Jacques Messier	Nil	314,041	Nil
Theodore H. Stanley	Nil	267,149	Nil
Samira Sakhia	Nil	24,042	Nil

Notes:

(1) Upon execution of the Reorganization on March 1, 2016, all outstanding DSUs for directors were settled in shares of Nuvo net of the cash tax obligation that was payable by Nuvo.

Directors' & Officers' Liability Insurance

The Corporation periodically renews and purchases insurance coverage for directors' and officers' liability. The policies in effect in 2016 were a policy from December 1, 2014 to March 1, 2016 (the "**2014 Policy**") that had a premium of \$104,000 and covered directors' and officers' liability for \$15,000,000 and a policy from March 1, 2016 to March 1, 2017 (the "**2016 Policy**") that has a premium of \$48,750 and covers directors' and officers' liability for \$15,000,000. The 2014 Policy provided for deductibles ranging from \$25,000 to \$100,000 and the 2016 Policy provides for deductibles ranging from \$25,000 to \$50,000 depending upon the nature of the claim made by the Corporation. However, there shall be no deductible for any claim made by a director or officer. This premium is paid entirely by the Corporation.

SPECIAL BUSINESS

Share Incentive Plan

The Board believes that the Share Incentive Plan is a key component of compensation and seeks to integrate compensation incentives with the development and successful execution of strategic and operating plans. The Corporation's Share Incentive Plan is designed to support the achievement of the Corporation's performance objectives and to ensure that the NEOs' and other key employees' interests are aligned with the success of the Corporation. The Share Incentive Plan consists of the Share Option Plan, Share Purchase Plan and Share Bonus Plan and is administered by the Board based on recommendations of the Compensation, Corporate Governance and Nominating Committee. The Share Incentive Plan or Options granted pursuant to the Share Option Plan may be amended or modified by the Board in accordance with the Share Incentive Plan without shareholder approval, provided that any such amendment or modification which would, among other things, (i) materially increase the benefits under the Share Incentive Plan or any Options granted pursuant to the Share Incentive Plan; (ii) increase the number of Common Shares which may be issued pursuant to the Share Incentive Plan (other than by permitted adjustments described in the Share Incentive Plan); or (iii) materially modify the requirements as to eligibility for participation in the Share Incentive Plan, shall only be effective upon such amendment or modification being approved by the shareholders of the Corporation if required by the TSX or any other applicable regulatory authority. Examples of amendments to the Share Incentive Plan that would not require shareholder approval (subject to the terms of the Share Incentive Plan) may include amendments that are necessary to comply with any applicable law or any requirement of the TSX (or any other stock exchange) and amendments that are of a "housekeeping" nature. No rights under the Share Incentive Plan and no option awarded pursuant to the provisions of the Share Incentive Plan are assignable or transferable by any participant (other than to the participant's estate in certain circumstances).

Further details regarding the Share Incentive Plan are discussed under the heading “Statement of Executive Compensation”.

The TSX requires that the Share Incentive Plan of the Corporation, along with any unallocated options, rights or other entitlements, receive shareholder approval at the Corporation’s annual meeting every three years. The Share Incentive Plan last received shareholder approval at the Corporation’s annual meeting on June 11, 2014. Accordingly, unless shareholder approval is obtained, all unallocated options, rights or other entitlements will be cancelled as of May 11, 2017, the date of the Meeting, and the Corporation will not be permitted to grant any further entitlements under the Share Incentive Plan; however, previously allocated Options or Common Shares will continue to be unaffected. If shareholder approval is obtained at the Meeting, the Corporation will not be required to seek further approval of the grant of unallocated options under the Share Option Plan or Common Shares under the Share Purchase Plan or Share Bonus Plan until the Corporation’s 2020 annual shareholders’ meeting (provided that such meeting is held on or prior to May 11, 2020). At the Meeting, shareholders of the Corporation will be asked to vote for an ordinary resolution affirming, ratifying and approving the Share Incentive Plan and approving all of the unallocated options and the unallocated Common Shares issuable pursuant to the Share Incentive Plan (the “**Share Incentive Plan Resolution**”).

The maximum number of Common Shares that may be issued under the Share Incentive Plan is a fixed maximum percentage of 15% of the outstanding Common Shares from time to time (being 1,732,634 Common Shares as of the date of this Circular based on the number of Common Shares currently outstanding); provided that the maximum number of Common Shares that may be issued under the Share Bonus Plan will not exceed 344,615 Common Shares (which is equal to 3% of the number of Common Shares outstanding immediately following the completion of the Reorganization).

As of the date of this Circular, the Corporation has Options outstanding under the Share Option Plan to purchase up to 1,158,906 Common Shares (representing approximately 10% of the issued and outstanding Common Shares). In addition, no Common Shares have been issued under the Share Purchase Plan or Share Bonus Plan. Therefore, as of the date of this Circular, there are approximately 573,728 Options and/or Common Shares (representing approximately 5% of the issued and outstanding Common Shares) available for issuance under the Share Incentive Plan).

The Board recommends the adoption of the Share Incentive Plan Resolution. To be effective, the Share Incentive Plan Resolution must be approved by not less than a majority of the votes cast by the shareholders of the Corporation who vote in respect of such resolution present in person, or represented by proxy, at the Meeting, excluding votes attaching to securities beneficially owned by certain directors and officers of the Corporation, who are considered “insiders” (as defined by the TSX) and who would be entitled to receive a benefit under the Share Incentive Plan. Accordingly, the votes attaching to 569,384 securities beneficially owned by insiders of the Corporation, representing approximately 4.9% of the issued and outstanding Common Shares of the Corporation, will be disqualified in counting the votes for the Share Incentive Plan Resolution. Unless otherwise indicated, the persons designated as proxyholders in the accompanying form of proxy will vote the Common Shares represented by such form of proxy, properly executed, for the Share Incentive Plan Resolution.

The text of the Share Incentive Plan Resolution to be submitted to shareholders at the Meeting is set out in Schedule A to this Circular. The Share Incentive Plan is available under the Corporation’s profile at www.sedar.com.

Unless otherwise instructed by a shareholder, the persons named in the accompanying form of proxy will vote “FOR” the Share Incentive Plan Resolution.

STATEMENT OF CORPORATE GOVERNANCE

Pursuant to National Instrument 58-101 Disclosure of Corporate Governance Practices (“NI 58-101”), each reporting issuer, such as the Corporation, must disclose on an annual basis, the corporate governance practices that it has adopted.

The Board believes that the Corporation’s corporate governance policies, procedures and practices, which are described below, are in compliance with applicable guidelines, rules and other legal requirements, and are appropriate in the current circumstances.

The Board recognizes that the Corporation’s corporate governance policies, procedures and practices cannot be static and that further refinements may be necessary as applicable legal and regulatory requirements and the Corporation’s circumstances evolve. The Board intends to continue to ensure that the Corporation’s systems and culture of corporate governance meet the legitimate expectations of shareholders, as well as applicable legal and regulatory requirements.

The Corporation’s Corporate Governance Guidelines (including the Board Charter) are set out in Schedule B to this Circular. The Board has approved the disclosure of the Corporation’s governance practices described below, on the recommendation of the Compensation, Corporate Governance and Nominating Committee.

Unless otherwise specifically stated, the information in this section is given as of the date hereof.

1. Board of Directors

a) Disclosure of the identity of directors who are independent.

Within the meaning of NI 58-101, four of the six nominated directors meet all requisite independence requirements. The four nominated directors considered “independent” are: Mr. David Copeland, private business consultant; Mr. Anthony Dobranowski, private business consultant; Dr. Jacques Messier, CEO, The Toronto Humane Society; and, Mr. Robert P. Harris, director, Aralez Pharmaceuticals Inc. and CannaRoyalty Corp.

b) Disclosure of the identity of directors who are not independent, and the basis for that determination.

Within the meaning of NI 58-101, two of the six nominated directors are not independent. The two non-independent nominated directors are: Mr. Daniel Chicoine, Chairman and former Co-Chief Executive Officer of the Corporation and Mr. John London, President and Chief Executive Officer of the Corporation.

c) Disclosure of whether or not a majority of directors are independent.

A majority of the Corporation’s six nominated directors are independent; their sole relationship with the Corporation is as a member of the Board and in some cases, as shareholders.

d) Identification of any director who is presently a director of any other reporting issuer.

As of December 31, 2016, the following directors are also directors of reporting issuers in the jurisdictions set out below:

Name	Company	Jurisdiction
Daniel Chicoine	Crescita Therapeutics Inc.	TSX
David A. Copeland	Crescita Therapeutics Inc.	TSX
Anthony E. Dobranowski	Crescita Therapeutics Inc.	TSX
Robert P. Harris	Aralez Pharmaceuticals Inc. CannaRoyalty Corp.	TSX and NASDAQ CSE
John C. London	Crescita Therapeutics Inc.	TSX

Name	Company	Jurisdiction
Samira Sakhia	Antibe Therapeutics Inc. Crescita Therapeutics Inc. Knight Therapeutics Inc. Profound Medical Corp.	TSXV TSX TSX TSXV

- e) *Disclosure of whether or not the independent directors hold regularly scheduled meetings at which non-independent directors and members of management are not in attendance. If the independent directors hold such meetings, disclose the number of meetings held since the beginning of the most recently completed financial year. If the independent directors do not hold such meetings, describe what the board does to facilitate open and candid discussion among its independent directors.*

To ensure free and open discussion and communication among directors, the independent directors will meet in executive session (with no members of senior management or non-independent directors present) after every regularly scheduled meeting of the Board and otherwise as those directors determine. The lead director will preside at these executive sessions, unless the directors present at such meetings determine otherwise. Further, the Compensation, Corporate Governance and Nominating Committee and the Audit Committee are comprised of independent directors and hold meetings with no members of senior management or non-independent directors present, unless the directors present at such meetings determine otherwise.

- f) *Disclosure of whether or not the chair of the board is an independent director. If the board has a chair or lead director who is an independent director, identify the independent chair or lead director, and describe his or her role and responsibilities.*

The chair of the Board, Daniel Chicoine, is not an independent director. The Board has appointed Mr. David Copeland, an independent director, as the lead director. The lead director's role is to ensure that the Board functions independently of management and that directors have an independent leadership contact. The lead director's responsibilities include acting as an independent liaison between the Board and senior management and ensuring that independent directors have had adequate opportunities to discuss issues without management present.

- g) *Disclosure of the attendance record of each director for all board meetings held since the beginning of the most recently completed financial year.*

During the fiscal year ended December 31, 2016, the Board met 18 times. The number of meetings attended by each director is set out below:

	Meetings Attended (#)
Daniel Chicoine	17
John London	17
Henrich Guntermann ⁽¹⁾	4
David Copeland	16
Klaus von Lindeiner ⁽¹⁾	4
Anthony Dobranowski	18
Jacques Messier	17
Theodore Stanley ⁽¹⁾	3
Samira Sakhia	13

Notes:

(1) Drs. Guntermann, von Lindeiner and Stanley each resigned from the Board of Directors on March 1, 2016.

2. Mandate of the Board

In fulfilling its statutory mandate and discharging its duty of stewardship of the Corporation, the Board assumes responsibility for those matters set forth in its Charter (which also is its mandate). The full text of the Board Charter is set out in Schedule 1 to the Corporate Governance Guidelines attached as Schedule B to this Circular.

3. Position Descriptions

- (a) *Disclosure of whether or not the board has developed written position descriptions for the chair and the chairs of each board committee. If the board has not developed such written position descriptions, disclosure of how the board delineates the role and responsibilities of each such position.*

The Board has developed written position descriptions for the chair of the Board, the lead director of the Board and the chairs of the Compensation, Corporate Governance and Nominating Committee and Audit Committee. The position descriptions are set out in Schedules 2, 3, 5 and 7, respectively, of the Corporate Governance Guidelines attached as Schedule B to this Circular.

- (b) *Disclosure of whether or not the board and CEO have developed a written position description for the CEO. If the board and CEO have not developed such a position description, describe how the board delineates the role and responsibilities of the CEO.*

A written position description has been developed for the CEO. Day-to-day executive management of the Corporation is managed by an executive management committee (the “**Executive Management Committee**”) consisting of the Chief Executive Officer, the President, the Vice President and Chief Financial Officer and the Vice President, Secretary & General Counsel. All managers report to and are supervised by one of the members of the Executive Management Committee. Major decisions respecting the day-to-day operations of the Corporation are made by the Executive Management Committee. The Executive Management Committee reviews the progress of the projects within the Corporation to ensure that the strategic plans approved by the Board are executed and implemented in a timely and effective manner. The Executive Management Committee members are in constant contact with each other, but also frequently meet on a formal basis to discuss and review matters affecting the Corporation.

4. Orientation and Continuing Education

- (a) *Description of what measures the board takes to orient new directors regarding:*
- (i) *the role of the board, its committees and its directors*
 - (ii) *the nature and operation of the Corporation’s business*

Senior management, working with the Board, will provide appropriate orientation and education for new directors to familiarize them with the Corporation and its business, as well as the expected contribution of individual directors. All new directors will participate in this program orientation and education, which should be completed within four months of a director first joining the Board.

The Compensation, Corporate Governance and Nominating Committee shall, when necessary or appropriate, and to the extent not otherwise being considered and addressed by the Board, in co-operation with the Corporation’s senior management, oversee an appropriate orientation and education for any new directors in order to familiarize them with the Corporation and its business.

- (b) *Description of what measures, if any, the board takes to provide continuing education for its directors. If the board does not provide continuing education, description of how the board ensures that its directors maintain the skill and knowledge necessary to meet their obligations as directors.*

Senior management will schedule periodic presentations for the Board to ensure they are aware of major business trends and industry practices as and when required. In addition, materials provided to the directors for meetings of the Board should provide the information needed for the directors to make informed judgments or engage in informed discussions. The chair of the Board and the lead director of the Board are responsible for ensuring the adequacy of such materials and that directors have sufficient time to review such materials.

5. Ethical Business Conduct

- (a) *Disclosure of whether or not the board has adopted a written code for the directors, officers and employees. If the board has adopted a written code:*
- (i) *disclosure of how a person or company may obtain a copy of the code*
 - (ii) *description of how the board monitors compliance with its code, or if the board does not monitor compliance, whether and how the board satisfies itself regarding compliance with its code*
 - (iii) *provide a cross-reference to any material change report filed since the beginning of the issuer's most recently completed financial year that pertains to any conduct of a director or executive officer that constitutes a departure from the code*

The Corporation has adopted a Code of Business Conduct and Ethics (the “**Code**”) applicable to directors, officers and employees. The purpose of the Code is to:

- Promote honest and ethical conduct
- Promote avoidance of conflicts of interest
- Promote full, fair, accurate, timely and understandable disclosure
- Promote compliance with applicable governmental laws, rules and regulations
- Promote the prompt internal reporting to an appropriate person of violation of the Code

All employees, officers and directors are provided with a copy of the Code and are required to sign an acknowledgement that they have read and agree to comply with the terms of the Code. A copy of the Code may be obtained from the Corporation's web site www.nuvopharmaceuticals.com.

It is the responsibility of the Compensation, Corporate Governance and Nominating Committee to review senior management's monitoring of compliance with the Code.

- (b) *Description of any steps the board takes to ensure directors exercise independent judgment in considering transactions and agreements in respect of which a director or executive officer has a material interest.*

Under the *Business Corporations Act* (Ontario) (the “**OBCA**”), to which the Corporation is subject, a general notice to the directors is generally required to be sent by a director or officer disclosing that he or she is a director or officer of or has a material interest in a person. It is the policy of the Corporation that an interested director or officer excuse himself or herself from the decision-making process (including discussions relating to the contract or transaction) pertaining to a contract or transaction in which he or she has an interest, other than in the case of certain permitted matters, such as matters related to his or her compensation as a director, permitted under the OBCA.

- (c) *Description of any other steps the board takes to encourage and promote a culture of ethical business conduct.*

The Board is aware and encourages management's practice of holding meetings with all the Corporation's employees during which senior management provides updates on the state of the Corporation's business. Where appropriate, these meetings are also used to remind employees of their responsibility under corporate policies, including the Code.

6. Nomination of Directors

- (a) *Description of the process by which the board identifies new candidates for board nomination.*

The Board, taking into consideration the recommendations of the Compensation, Corporate Governance and Nominating Committee, will be responsible for selecting the nominees for election to the Board, for appointing directors to fill vacancies, and determining whether a nominee or appointee is independent.

The Compensation, Corporate Governance and Nominating Committee develops criteria for selecting new directors, assists the Board by identifying individuals qualified to become members of the Board (consistent with criteria approved by the Board) and develops a list of director nominees for the annual meeting of shareholders and for each committee of the Board and the chair of each committee. In doing so, the Compensation, Corporate Governance and Nominating Committee periodically reviews the competencies, skills and personal qualities required of directors to add value to the Corporation in light of the opportunities and risks facing the Corporation and the Corporation's proposed strategies, the need to ensure that a majority of the Board is comprised of individuals who meet the independence requirements of applicable legislation and stock exchange requirements, and the policies of the Board with respect to director tenure, retirement and succession and director commitments.

- (b) *Disclosure of whether or not the board has a nominating committee composed entirely of independent directors. If the board does not have a nominating committee composed of entirely independent directors, description of the steps the board takes to encourage an objective nomination process.*

The Compensation, Corporate Governance and Nominating Committee is comprised entirely of independent directors. The members of the Committee are: Jacques Messier, Anthony Dobranowski, and Samira Sakhia.

- (c) *If the board has a nominating committee, describe the responsibilities, powers and operation of the nominating committee.*

The Compensation, Corporate Governance and Nominating Committee Charter establishes the purpose, composition, responsibilities, and operation of the Compensation, Corporate Governance and Nominating Committee. The Compensation, Corporate Governance and Nominating Committee Charter is set out in Schedule 4 to the Corporate Governance Guidelines attached as Schedule B to this Circular.

7. Compensation

- (a) *Description of the process by which the board determines the compensation for the Corporation's directors and officers.*

The form and amount of director compensation will be determined by the Board from time to time upon the recommendation of the Compensation, Corporate Governance and Nominating Committee. In addition, the Board shall assess the performance of the Corporation's senior management and periodically monitor the compensation levels of such senior management based on determinations and recommendations made by the Compensation, Corporate Governance and Nominating Committee.

The Compensation, Corporate Governance and Nominating Committee develops a compensation structure for the Board and senior management, including salaries, annual and long-term incentive plans and plans involving share options, share issuances and share unit awards. The Compensation, Corporate Governance and Nominating Committee reviews the compensation and performance of senior management at least annually, with a view to maintaining a compensation program for senior management at a fair and competitive level, consistent with the best interests of the Corporation, and periodically reviews the compensation of directors to, among other things, ensure their compensation appropriately reflects the responsibilities they are assuming.

In discharging its mandate, the Compensation, Corporate Governance and Nominating Committee has the authority to retain and receive advice from outside advisors.

- (b) *Disclosure of whether or not the board has a compensation committee composed entirely of independent directors.*

The Compensation, Corporate Governance and Nominating Committee is comprised entirely of independent directors. The members of the Committee are: Jacques Messier, Anthony Dobranowski, and Samira Sakhia.

- (c) *If the board has a compensation committee, description of the responsibilities, powers and operation of the compensation committee.*

The Compensation, Corporate Governance and Nominating Committee Charter establishes the purpose, composition, responsibilities, and operation of the Compensation, Corporate Governance and Nominating Committee. The Compensation, Corporate Governance and Nominating Committee Charter is set out in Schedule 4 to the Corporate Governance Guidelines attached as Schedule B to this Circular.

- (d) *If a compensation consultant or advisor has, at any time since the beginning of the Corporation's most recently completed financial year, been retained to assist in determining the compensation for any of the Corporation's directors and officers, disclosure of the identity of the consultant or advisor and summary of the mandate for which they were retained.*

The Board retained and obtained executive compensation reports and recommendations from Radford in 2010 to review the structure and value of compensation packages paid to the senior management to ensure that they are effective, competitive and comparable to similar companies. Radford did not provide the Compensation, Corporate Governance and Nominating Committee and the Board with advice during 2016.

8. Other Board Committees

- (a) *If the board has standing committees other than the audit, compensation and nominating committees, identification of the committees and description of their function.*

In addition to its function with respect to compensation and nomination matters, the Compensation, Corporate Governance and Nominating Committee is intended to develop appropriate corporate governance principles for the Corporation and undertake such other initiatives to enable the Board to provide effective corporate governance. Its responsibilities include periodically reviewing the adequacy of the Corporation's Corporate Governance Guidelines, the practices of the Board to ensure compliance with the Corporation's Corporate Governance Guidelines, the relationship between senior management and the Board with a view to ensuring that the Board is able to function independently of senior management and making recommendations to the Board with respect to such matters. The Compensation, Corporate Governance and Nominating Committee Charter is set out in Schedule 4 to the Corporate Governance Guidelines attached as Schedule B to this Circular.

9. Assessment

- (a) *Disclosure of whether or not the board, its committees and individual directors are regularly assessed with respect to their effectiveness and contribution. If assessments are not regularly conducted, describe how the board satisfies itself that the board, its committees, and its individual directors are performing effectively.*

The Compensation, Corporate Governance and Nominating Committee oversees periodic reviews of the Board's, the Audit Committee's and individual directors' performance.

10. Director Term Limited and Other Mechanisms of Board Renewal

- (a) *Disclosure of whether or not the Corporation has adopted term limits for the directors on its board or other mechanisms of board renewal and, if so, include a description of those director term limits or other mechanisms of board renewal. If the Corporation has not adopted director term limits or other mechanisms of board renewal, disclosure of why it has not done so.*

Each director serves on the Board until the next annual meeting of shareholders of the Corporation or until a successor is duly elected or appointed. The Board does not have a limit on the number of consecutive terms for which a director may serve. While there is benefit to adding new perspectives to the Board from time to time, there are also benefits to having continuity and directors having in depth knowledge of each facet of the Corporation's business, which necessarily takes time to develop. The Board believes that the imposition of term limits for its directors may run the risk of excluding experienced and potentially valuable Board members as a result of an arbitrary determination. The Board relies on thorough director assessment procedures for evaluating its members, and uses rigorous identification and selection processes for new directors, having regard to a variety of factors. Through these processes, the Board believes that it is well-positioned to address any problems or deficiencies that may arise in an appropriate manner without having to adopt mandated term limits.

11. Consideration of the Representation of Women in the Director Identification and Selection Process and in Executive Officer Appointments; the Corporation's Targets Regarding the Representation of Women on the Board and in Executive Officer Positions; and Number of Women on the Board and in Executive Officer Positions

- (a) *Disclosure of whether and, if so, how the board or nominating committee considers the level of representation of women on the board in identifying and nominating candidates for election or re-election to the board. If the Corporation does not consider the level of representation of women on the board in identifying and nominating candidates for election or re-election to the board, disclosure of the Corporation's reasons for not doing so.*
- (b) *Disclosure of whether and, if so, how the Corporation considers the level of representation of women in executive officer positions when making executive officer appointments. If the Corporation does not consider the level of representation of women in executive officer positions when making executive officer appointments, disclosure of the Corporation's reasons for not doing so.*
- (c) *Disclosure of whether the Corporation has adopted a target regarding women on the Corporation's board. If the Corporation has not adopted a target, disclosure of why it has not done so.*
- (d) *Disclosure of whether the Corporation has adopted a target regarding women in executive officer positions of the Corporation. If the Corporation has not adopted a target, disclosure of why it has not done so.*
- (e) *Disclosure of the number and proportion (in percentage terms) of directors on the Corporation's board who are women.*
- (f) *Disclosure of the number and proportion (in percentage terms) of executive officers of the Corporation, including all major subsidiaries of the Corporation, who are women.*

Of the six current board of directors of the Corporation, one is a woman (representing 17% of the current directors). Of the four current executive officers of the Corporation, two are woman (representing 50% of the current executive officers). While the Corporation strongly supports the principle of diversity in its leadership, of which gender is an important aspect, the Corporation does not have a policy or targets regarding the representation of women on the Board or senior management, as the Board does not believe that quotas or strict rules necessarily result in the identification or selection of the best candidates. Rather, the identification and selection process is made based on a variety of criteria, including the diversity of viewpoints, backgrounds, experiences and other demographics, but also expertise, skills, character, business experience and other relevant factors. Accordingly, in searches for new directors or executive officers, the Board considers the level of female representation and diversity within its leadership ranks and this is just one of several factors used in its search process.

OTHER BUSINESS

At the time of this Circular, the Corporation knows of no matter to come before the Meeting other than the matters referred to in the accompanying Notice of Meeting.

AUDIT COMMITTEE

Information concerning the audit committee of the Corporation can be found in the Corporation's Annual Information Form dated March 1, 2017 and available at www.sedar.com.

ADDITIONAL INFORMATION

Additional information relating to the Corporation, including financial information related to the Corporation is provided in its comparative financial statements for the fiscal year ended December 31, 2016 and management's discussion and analysis is available at www.sedar.com, or may be obtained on request and without charge by contacting Mary-Jane Burkett, Vice President and CFO, 7560 Airport Road, Unit 10, Mississauga, Ontario L4T 4H4.

The Corporation's Report to Shareholders for the fiscal year ended December 31, 2016, containing the Corporation's consolidated financial statements for the fiscal year ended December 31, 2016, is being mailed to the shareholders of the Corporation that requested such information with the Notice of Meeting and this Circular.

BOARD APPROVAL

The contents and mailing of this Circular have been approved by the directors of the Corporation.

BY ORDER OF THE BOARD OF DIRECTORS

A handwritten signature in black ink, appearing to read 'John London', with a long horizontal stroke extending to the right.

John London
Chief Executive Officer

Mississauga, Ontario
April 5, 2017

Schedule A

BE IT RESOLVED AS AN ORDINARY RESOLUTION OF THE SHAREHOLDERS THAT:

1. The Third Amended and Restated Share Incentive Plan (the “**Plan**”) of Nuvo Pharmaceuticals Inc. (the “**Corporation**”) substantially in the form presented to the directors of the Corporation and described in the management information circular of the Corporation dated April 5, 2017 be and is hereby affirmed, ratified and approved.
2. All unallocated options and unallocated common shares issuable pursuant to the Plan be and are hereby approved.
3. The Corporation shall have the ability to continue issuing options and common shares under the Plan until May 11, 2020, which is the date that is three (3) years from the date of the shareholder meeting at which shareholder approval of the Plan is being sought.
4. Each director and officer of the Corporation be and is hereby authorized and directed, for and on behalf of the Corporation, to execute and deliver all such documents and to do all such other acts and things as such director or officer may determine to be necessary or advisable to give effect to this resolution, the execution and delivery of any such document or the doing of any such other act or thing being conclusive evidence of such determination.

Schedule B

NUVO PHARMACEUTICALS INC. (the “Corporation”)

CORPORATE GOVERNANCE GUIDELINES

INTRODUCTION

The Board of Directors is committed to fulfilling its statutory mandate to supervise the management of the business and affairs of the Corporation with the highest standards of ethical conduct and in the best interests of the Corporation and its shareholders. The Board of Directors, acting on the recommendation of its Compensation, Corporate Governance and Nominating Committee (the “CCGNC”),¹ has adopted these corporate governance guidelines to promote the effective functioning of the Board of Directors and its committees, to promote the interests of shareholders, and to establish a common set of expectations as to how the Board of Directors, its committees, individual directors and senior management should perform their functions.

The following schedules are attached to these guidelines and form a part hereof:

Schedule 1	-	Board of Directors Charter
Schedule 2	-	Position Description for Chair of the Board
Schedule 3	-	Position Description for Lead Director of the Board
Schedule 4	-	CCGNC Charter
Schedule 5	-	Position Description for CCGNC Chair
Schedule 6	-	Audit Committee Charter
Schedule 7	-	Position Description for Audit Committee Chair

GUIDELINES

Board of Directors’ Responsibilities

The business and affairs of the Corporation are managed by or under the supervision of the Board of Directors in accordance with applicable legislation, regulatory requirements and policies of the Canadian Securities Administrators. The responsibility of the Board of Directors is to provide direction and oversight and overall stewardship of the Corporation. The Board of Directors approves the strategic direction of the Corporation and oversees the performance of the Corporation’s business and senior management. The senior management of the Corporation is responsible for presenting long-term strategic plans to the Board of Directors for review and approval and for implementing the Corporation’s strategic direction.

The Board of Directors also expects management to report short-term results and long-term goals, on a frequent and timely basis. The Board of Director receives regular input and reports from management through the President and Chief Executive Officer, as well as from the Vice President Finance and Chief Financial Officer and other senior management.

In performing their duties, the primary responsibility of the directors is to exercise their business judgment in what they reasonably believe to be the best interests of the Corporation. In discharging that obligation, directors should be entitled to rely on the honesty and the integrity of the Corporation’s senior management and outside advisors and auditors. The directors also should be entitled to have the Corporation purchase reasonable directors’ and officers’ liability insurance on their behalf, and to the benefits of indemnification to the fullest extent permitted by applicable law and to exculpation as provided by applicable law.

¹ Prior to the implementation of these guidelines, the relevant committee was called the “Compensation and Corporate Governance Committee”. In connection with the adoption and implementation of these guidelines, the committee’s name is being changed.

In fulfilling its statutory mandate and discharging its duty of stewardship of the Corporation, the Board of Directors assumes responsibility for those matters set forth in its Charter (which also is its mandate).

Board of Directors' Size

It is the current view of the Board of Directors that the Board of Directors should consist of no more than seven members to facilitate its effective functioning.

Chair of the Board of Directors

The Board of Directors believes that, at this time, it is appropriate for the Corporation to have a Chair who is not independent. The Chair should carry out his or her responsibilities in accordance with the position description for the Chair.

Because the Chair is not independent, a Lead Director has been appointed by the Board of Directors. The Lead Director should carry out his or her responsibilities in accordance with the written position description for the Lead Director.

Selection of Directors

As provided in the CCGNC's Charter, the CCGNC will be responsible for identifying and recommending to the Board of Directors individuals qualified to become members of the Board of Directors, based primarily on the following criteria:

- judgment, character, expertise, skills and knowledge useful to the oversight of the Corporation's business,
- diversity of viewpoints, backgrounds, experiences and other demographics,
- business or other relevant experience, and
- the extent to which the interplay of the individual's expertise, skills, knowledge and experience with that of other members of the Board of Directors will build a board that is effective, collegial and responsive to the needs of the Corporation.

The CCGNC also will be responsible for initially assessing whether a candidate would be independent (and in that process applying the "Categorical Standards for Determining Independence of Directors" (that are appended to the Board of Directors Charter) and advising the Board of Directors of that assessment.

The Board of Directors, taking into consideration the recommendations of the CCGNC, will be responsible for selecting the nominees for election to the Board of Directors, for appointing directors to fill vacancies, and determining whether a nominee or appointee is independent.

Committee Membership

Each of the Audit Committee and the CCGNC will be composed of no fewer than three members, each of whom will satisfy the membership criteria set out in the relevant committee charter. Members of committees will be appointed by the Board of Directors upon the recommendation of the CCGNC. A director may serve on more than one committee and committee membership may be rotated periodically as necessary or advisable. The Board of Directors, taking into account the recommendation of the CCGNC, generally will designate one member of each committee as chair of that committee. Committee chairs shall carry out their responsibilities in accordance with their respective position descriptions. Committee chairs may be rotated periodically as well.

Evaluating Board of Directors and Committee Performance

The CCGNC will conduct an annual assessment of the effectiveness of the Board of Directors and each of the committees.

Board of Directors and Committee Meetings

The Board of Directors and each committee should meet as provided in its respective charter.

An agenda for each meeting of the Board of Directors and each committee meeting will be provided to each director and each member of the relevant committee. Any director or member of a committee may suggest the inclusion of subjects on the agenda of meetings of the Board of Directors or a committee. Each director and each member of a committee is free to raise at a meeting of the Board of Directors or a committee meeting, respectively, subjects that are not on the agenda for that meeting.

Materials provided to the directors for meetings of the Board of Directors and committee meetings should provide the information needed for the directors and members of the committee, respectively, to make informed judgments or engage in informed discussions.

To ensure free and open discussion and communication among directors, the independent directors will meet in executive session (with no members of senior management or non-independent directors present) after every regularly scheduled meeting of the Board of Directors and otherwise as those directors determine. The Lead Director will preside at these executive sessions, unless the directors present at such meetings determine otherwise. Any interested party may communicate directly with the Lead Director, who may invite such person to address an executive session.

Unless the chair of a committee otherwise determines, the agenda, materials and minutes for each committee meeting will be available on request to all directors, and all directors will be free to attend any committee meeting. All meetings of a committee will have a session in which the members of the committee will meet with no non-committee members present and at any time in a meeting of a committee, directors who are not members may be asked to leave the meeting to ensure free and open discussion and communication among members of the committee. It is at the Board of Directors' discretion as to whether directors who are not members of a committee will be compensated for attending meetings of that committee.

Director Compensation

As provided for in the CCGNC Charter, the form and amount of director compensation will be determined by the Board of Directors from time to time upon the recommendation of the CCGNC.

Expectations of Directors

The Board of Directors has developed a number of specific expectations of directors to promote the discharge by the directors of their responsibilities and to promote the efficient conduct of the Board of Directors.

Commitment and Attendance. All directors should strive to attend all meetings of the Board of Directors and the committees of which they are members. Attendance by telephone or video conference may be used when necessary to facilitate a director's attendance.

Participation in Meetings. Each director should be sufficiently familiar with the business of the Corporation, including its financial statements and capital structure, and the risks it faces, to ensure active and effective participation in the deliberations of the Board of Directors and of each committee on which he or she serves.

Loyalty and Ethics. In their roles as directors, all directors owe a duty of loyalty to the Corporation. This duty of loyalty mandates that the best interests of the Corporation take precedence over any other interest possessed by a director. Directors should conduct themselves in accordance with the Corporation's Code of Business Conduct and Ethics.

Contact with Senior Management and Employees. All directors should be free to contact any of the members of the Corporation's senior management at any time to discuss any aspect of the Corporation's business. The Board of Directors expects that there will be frequent opportunities for directors to meet with

members of senior management in meetings of the Board of Directors and committees, or in other formal or informal settings.

Confidentiality. The proceedings and deliberations of the Board of Directors and its committees are confidential. Each director will maintain the confidentiality of information received in connection with his or her service as a director.

Orientation and Continuing Education

Senior management, working with the Board of Directors, will provide appropriate orientation and education for new directors to familiarize them with the Corporation and its business, as well as the expected contribution of individual directors. All new directors will participate in this program orientation and education, which should be completed within four months of a director first joining the Board of Directors. In addition, senior management will schedule periodic presentations for the Board of Directors to ensure they are aware of major business trends and industry practices as and when required.

SCHEDULE 1

NUVO PHARMACEUTICALS INC. (the “Corporation”)

BOARD OF DIRECTORS CHARTER

PURPOSE

The Board of Directors is elected by the Corporation’s shareholders to supervise the management of the business and affairs of the Corporation, in the best interests of the Corporation. The Board of Directors shall:

- Review and approve the strategic plan and business objectives of the Corporation that are submitted by senior management and monitor the implementation by senior management of the strategic plan. During at least one meeting each year, the Board of Directors will review the Corporation’s long-term strategic plans and the principal issues that the Corporation expects to face in the future.
- Review the principal strategic, operational, reporting and compliance risks for the Corporation and oversee, with the assistance of the Audit Committee, the implementation and monitoring of appropriate risk management systems and the monitoring of risks.
- Ensure, with the assistance of the Compensation, Corporate Governance and Nominating Committee (the “CCGNC”), the effective functioning of the Board of Directors and its committees in compliance with applicable corporate governance requirements, and that such compliance is reviewed periodically by the CCGNC.
- Ensure internal controls and management information systems for the Corporation are in place and are evaluated and reviewed periodically on the initiative of the Audit Committee.
- Assess the performance of the Corporation’s senior management and periodically monitor the compensation levels of such senior management based on determinations and recommendations made by the CCGNC.
- Ensure that the Corporation has in place a policy for effective communication with shareholders, other stakeholders and the public generally.
- Review and, where appropriate, approve the recommendations made by the various committees of the Board of Directors.

COMPOSITION

The Board of Directors collectively should possess a broad range of skills, expertise, industry and other knowledge, and business and other experience useful to the effective oversight of the Corporation’s business. The Board of Directors should be comprised of that number of individuals which will permit the Board of Directors’ effective functioning. The appointment and removal of directors shall occur in accordance with the *Business Corporations Act* (Ontario) and the Corporation’s by-laws. A majority of the Board of Directors should meet the independence requirements of applicable legislation, regulatory requirements and policies of the Canadian Securities Administrators. The Board of Directors has adopted a set of categorical standards for determining whether directors satisfy those requirements for independence. A copy of those standards is attached as **Appendix A**. The Board of Directors, upon the recommendation of the CCGNC, shall designate the Chair and Lead Director by majority vote of the Board of Directors.

MEETINGS

The Board of Directors shall meet at least four times each year and more frequently as circumstances require. All members of the Board of Directors should strive to be at all meetings. The Board of Directors may meet separately,

periodically, without senior management, and may request any member of the Corporation's senior management or the Corporation's outside advisors or auditor to attend meetings of the Board of Directors.

COMMITTEES

The Board of Directors may delegate authority to individual directors and committees where the Board of Directors determines it is appropriate to do so. The Board of Directors expects to accomplish a substantial amount of its work through committees and shall form at least the following two committees: the Audit Committee and the CCGNC. The Board of Directors may, from time to time, establish or maintain additional standing or special committees as it determines to be necessary or appropriate. Each committee should have a written charter and should report regularly to the Board of Directors, summarizing the committee's actions and any significant issues considered by the committee.

INDEPENDENT ADVICE

In discharging its mandate, the Board of Directors shall have the authority to retain (and authorize the payment by the Corporation of) and receive advice from special legal, accounting or other advisors as the Board of Directors determines to be necessary to permit it to carry out its duties.

ANNUAL EVALUATION

Annually, the Board of Directors through the CCGNC shall, in a manner it determines to be appropriate:

- Conduct a review and evaluation of the performance of the Board of Directors and its members and committees, including the compliance of the Board of Directors with this Charter. This evaluation will focus on the contribution of the Board of Directors to the Corporation and specifically focus on areas in which the directors and senior management believe that the contribution of the Board of Directors could be improved.
- Review and assess the adequacy of this Charter and the position description for the Chair and Lead Director and make any improvements the Board of Directors determines to be appropriate.

APPENDIX A

CATEGORICAL STANDARDS FOR DETERMINING INDEPENDENCE OF DIRECTORS

For a director to be considered independent under the rules of the Canadian Securities Administrators, he or she must have *no direct or indirect material relationship with the Corporation*, being a relationship that could, in the view of the Board of Directors, reasonably interfere with the exercise of a director's independent judgement.

The Board of Directors, upon the recommendation of the CCGNC, has considered the types of relationships that could reasonably be expected to be relevant to the independence of a director of the Corporation. The Board of Directors has determined that:

1. A director's interests and relationships arising solely from his or her (or any immediate family members²) shareholdings in the Corporation are not, in and of themselves, a bar to independence.
2. Unless a specific determination to the contrary is made by the CCGNC as a result of there being another direct or indirect material relationship with the Corporation, a director will be independent unless currently, or at any time within the past three years, he or she or any immediate family member:
 - Employment: Is (or has been) an officer or employee (or, in the case of an immediate family member, an executive officer) or (in the case of the director only) of the Corporation or any of its subsidiaries (collectively, the "**Corporation Group**") or is actively involved in the day-to-day management of the Corporation;
 - Direct Compensation: Receives (or has received) direct compensation during any twelve-month period from the Corporation Group (other than director fees and committee fees and pension or other forms of deferred compensation for prior service, provided it is not contingent on continued service);³
 - Auditor Relationship. Is (or has been) a partner or employee of a firm that is the Corporation's auditor (provided that in the case of an immediate family member, he or she participates in its audit, assurance or tax compliance (but not tax planning practice)) and if during that time, he or she or an immediate family member was a partner or employee of that firm but no longer is such, he or she or the immediate family member personally worked on the Corporation's audit;
 - Material Commercial Relationship. Has (or has had), or is an executive officer, employee or significant shareholder of a person that has (or has had), a significant commercial relationship with the Corporation Group;
 - Cross-Compensation Committee Link. Is employed as an executive officer of another entity whose compensation committee (or similar body) during that period of employment included a current executive officer of the Corporation; or
 - Material Association. Has (or has had) a close association with an executive officer of the Corporation.

Notwithstanding the foregoing, no director will be considered independent if applicable securities legislation, rules or regulations expressly prohibit such person from being considered independent.

² A (i) spouse, parent, child, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, sister-in-law, or (ii) any person (other than domestic employees) who shares that director's home.

³ Employment as an interim chair or an interim Chief Executive Officer need not preclude a director from being considered independent following the end of that employment. Receipt of compensation by an immediate family member need not preclude a director from being independent if that family member is a non-executive employee.

SCHEDULE 2

NUVO PHARMACEUTICALS INC. (the “Corporation”)

CHAIR OF THE BOARD OF DIRECTORS

POSITION DESCRIPTION

The Chair is a director who is designated by the Board of Directors to assist the Board of Directors in fulfilling its duties effectively and efficiently.

The designation of the Chair shall take place annually at the first meeting of the Board of Directors after a meeting of the shareholders at which directors are elected, provided that if the designation is not so made, the director who is then serving as Chair shall continue as Chair until his or her successor is appointed.

Chair

The responsibilities of the Chair include:

- acting as a liaison between the Board of Directors and management,
- promoting a thorough understanding by members of the Board of Directors and senior management of the duties and responsibilities of the Board of Directors,
- recommending procedures to enhance the work of the Board of Directors and cohesiveness among directors,
- ensuring that the Board of Directors is appropriately involved in approving strategy and supervising senior management’s progress against achieving that strategy,
- in connection with meetings of the Board of Directors:
 - taking the principal initiative in scheduling meetings of the Board of Directors,
 - organizing and presenting the agenda for Board of Directors meetings such that,
 - all of the responsibilities assigned to the Board of Directors under the terms of its Charter are discharged on a timely and diligent basis, and
 - members of the Board of Directors have input into the agendas,
 - monitoring the adequacy of materials provided to the Board of Directors by senior management in connection with the Board of Directors deliberations,
 - ensuring that members of the Board of Directors have sufficient time to review the materials provided to them and to fully discuss the business that comes before the Board of Directors, and
 - presiding over meetings of the Board of Directors,
- on an annual basis, facilitating the annual performance review and evaluation of the Board of Directors and its members in accordance with the Charter and facilitating the assessment of the adequacy of the Charter, and
- performing such other functions as may be ancillary to the duties and responsibilities described above and as may be delegated to the Chair by the Board of Directors from time to time.

SCHEDULE 3

NUVO PHARMACEUTICALS INC. (the “Corporation”)

LEAD DIRECTOR OF THE BOARD

POSITION DESCRIPTION

The Lead Director is an “independent” director who is designated by the Board of Directors to assist the Board of Directors in fulfilling its duties independent of management. The Lead Director role also exists to ensure that directors have an independent leadership contact.

The designation of the Lead Director shall take place annually at the first meeting of the Board of Directors after a meeting of the shareholders at which directors are elected, provided that if the designation is not so made, the director who is then serving as Lead Director shall continue as Lead Director until his or her successor is appointed.

Lead Director

The responsibilities of the Lead Director include:

- acting as an independent liaison between the Board of Directors and senior management,
- together with the Chair, promoting a thorough understanding by members of the Board of Directors and management of the duties and responsibilities of the Board of Directors,
- together with the Chair, recommending procedures to enhance the work of the Board of Directors,
- working with the Chair to ensure that the Board of Directors is appropriately involved in approving strategy and supervising management’s progress against achieving that strategy,
- ensuring that independent directors have had adequate opportunities to discuss issues without management present,
- communicating to senior management, as appropriate, the results of private discussions among independent directors,
- together with the Chair, in connection with meetings of the Board of Directors:
 - scheduling meetings of the Board of Directors,
 - organizing and presenting the agenda for Board of Directors meetings such that,
 - all of the responsibilities assigned to the Board of Directors under the terms of its Charter are discharged on a timely and diligent basis, and
 - members of the Board of Directors have input into the agendas,
 - monitoring the adequacy of materials provided to the Board of Directors by management in connection with the Board of Directors deliberations,
 - ensuring that members of the Board of Directors have sufficient time to review the materials provided to them and to fully discuss the business that comes before the Board of Directors,
 - presiding over meetings of the Board of Directors where the Chair is not in attendance, and

- presiding over executive meetings of the Board of Directors, its non-management directors and its independent directors,
- on an annual basis, facilitating the annual performance review and evaluation of the Board of Directors and its members in accordance with the Charter and facilitating the assessment of the adequacy of the Charter,
- presiding over meetings of the Corporation's shareholders when the Chair is absent or when the Board of Directors determines the Lead Director should do so, and
- performing such other functions as may be ancillary to the duties and responsibilities described above and as may be delegated to the Lead Director by the Board of Directors from time to time.

SCHEDULE 4

NUVO PHARMACEUTICALS INC. (the “Corporation”)

COMPENSATION, CORPORATE GOVERNANCE AND NOMINATING COMMITTEE CHARTER

PURPOSE

The Compensation, Corporate Governance and Nominating Committee (the “CCGNC”) is appointed by the Board of Directors to, when necessary or appropriate, and to the extent not otherwise being considered and addressed by the Board of Directors:

- Recruit, develop and retain senior management,
- conduct performance evaluations and determine compensation of senior management,
- develop succession planning systems and processes relating to senior management,
- develop a compensation structure for the Board of Directors and senior management, including salaries, annual and long-term incentive plans and plans involving share options, share issuances and share unit awards,
- deal with all material benefit plan matters,
- develop to the Board of Directors appropriate corporate governance principles for the Corporation,
- develop procedures for the conduct of Board meetings, and the proper discharge of the Board of Directors’ mandate,
- oversee periodic reviews of the Board of Directors’, its committees’ and individual directors’ performance and the assessment of the Board of Directors’ and committees’ charters,
- undertake such other initiatives to enable the Board of Directors to provide effective corporate governance,
- develop criteria for selecting new directors,
- assist the Board of Directors by identifying individuals qualified to become members of the Board of Directors (consistent with criteria approved by the Board of Directors),
- develop a list of director nominees for the annual meeting of shareholders and for each committee of the Board of Directors and the chair of each committee, and
- make recommendations, if required, to the Board of Directors with respect to the matters listed above.

REPORTS

The CCGNC shall report to the Board of Directors on a regular basis, and in any event at least annually. The CCGNC shall prepare a report on the Corporation’s system of corporate governance practices for inclusion in the management information circular or other public disclosure documents of the Corporation. The CCGNC also shall prepare a report disclosing the extent (if any) to which the Corporation does not comply with the corporate governance guidelines of applicable legislation, regulatory requirements and policies of the Canadian securities administrators.

COMPOSITION

The members of the CCGNC shall be three directors who are appointed (and may be replaced) by the Board of Directors. The appointment of members of the CCGNC shall take place annually at the first meeting of the Board of Directors after a meeting of shareholders at which directors are elected, provided that if the appointment of members of the CCGNC is not so made, the directors who are then serving as members of the CCGNC shall continue as members of the CCGNC until their successors are appointed. The Board of Directors may appoint a member to fill a vacancy that occurs in the CCGNC between annual elections of directors. Any member of the CCGNC may be removed from the CCGNC by a resolution of the Board of Directors. Unless the Chair is appointed by the Board of Directors, the members of the CCGNC may designate a Chair by majority vote of the members of the CCGNC.

Each of the members of the CCGNC shall meet the Corporation's "Categorical Standards for Determining Independence of Directors". Each member of the CCGNC shall have or develop an understanding of corporate governance principles and practices.

RESPONSIBILITIES

Corporate Governance and Compliance

The CCGNC shall, when necessary or appropriate, and to the extent not otherwise being considered and addressed by the Board of Directors:

- Review from time to time the size of the Board of Directors and number of directors who are independent for the purpose of applicable requirements,
- periodically review the adequacy of the Corporate Governance Guidelines and Code of Business Conduct and Ethics of the Corporation and determine any proposed changes to those Guidelines or that Code to the Board of Directors for approval,
- be responsible for granting any waivers from the application of the Corporation's Code of Business Conduct and Ethics and review senior management's monitoring of compliance with that Code,
- periodically review the practices of the Board of Directors (including separate meetings of non-management directors and of independent directors) to ensure compliance with the Corporate Governance Guidelines of the Corporation, periodically review the powers, mandates and performance, and the membership of the various committees of the Board of Directors,
- periodically review the relationship between senior management and the Board of Directors with a view to ensuring that the Board of Directors is able to function independently of senior management, and
- make recommendations, if required, to the Board of Directors with respect to the matters listed above.

Compensation

The CCGNC shall, when necessary or appropriate, and to the extent not otherwise being considered and addressed by the Board of Directors:

- At least annually, review with the Chief Executive Officers the long term goals and objectives of the Corporation which are relevant to the Chief Executive Officers' compensation, evaluate the Chief Executive Officers' performance in light of those goals and objectives, determine and recommend to the independent directors for approval, the Chief Executive Officers' compensation based on that evaluation, and report to the Board of Directors thereon. In determining the Chief Executive Officers' compensation, the CCGNC shall consider the Corporation's performance, the value of similar incentive awards to Chief Executive Officers at comparable companies, and the awards given to the Chief Executive Officers in past years, with a view to maintaining a compensation program for the Chief Executive Officers at a fair and competitive level, consistent with the best interests of the Corporation,

- at least annually, in consultation with the Chief Executive Officers, review the compensation of all members of senior management other than the Chief Executive Officer, with a view to maintaining a compensation program for the senior management at a fair and competitive level, consistent with the best interests of the Corporation,
- periodically review compensation of directors, the Chair, the Lead Director and those acting as committee chairs to, among other things, ensure their compensation appropriately reflects the responsibilities they are assuming,
- fix and determine (and, as it determines to be appropriate, delegate the authority to fix and determine) awards (and the vesting criteria thereof) to employees of stock or stock options pursuant to any of the Corporation's equity-based plans now or from time to time in effect or otherwise as permitted by applicable legislation, regulatory requirements and policies of the Canadian securities administrators and applicable stock exchanges and exercise such other power and authority as may be permitted or required under those plans,
- in co-operation with the Corporation's senior management, oversee the human resources policies and programs which are of strategic significance to the Corporation,
- review all executive compensation disclosure prior to public disclosure by the Corporation,
- periodically review with the Board of Directors the succession plans relating to the senior positions and make selections of individuals to occupy these positions, and
- make recommendations, if required, to the Board of Directors with respect to the matters listed above.

Director Candidates

The CCGNC shall, when necessary or appropriate, and to the extent not otherwise being considered and addressed by the Board of Directors:

- Review periodically the competencies, skills and personal qualities required of directors to add value to the Corporation in light of the opportunities and risks facing the Corporation and the Corporation's proposed strategies, the need to ensure that a majority of the Board of Directors is comprised of individuals who meet the independence requirements of applicable legislation and stock exchange requirements, and the policies of the Board of Directors with respect to director tenure, retirement and succession and director commitments,
- In co-operation with the Corporation's senior management, oversee an appropriate orientation and education for any new directors in order to familiarize them with the Corporation and its business,
- Actively seek individuals qualified (in context of the Corporation's needs and any formal criteria established by the Board of Directors) to become members of the Board of Directors for recommendation to the Board of Directors,
- Review the membership and allocation of directors to the various committees of the Board of Directors, and the chairs thereof,
- Establish procedures for the receipt of comments from all directors to be included in an periodic assessment of the Board of Director's performance,
- If the need should arise, approve the engagement of independent advisors for individual directors at the expense of the Corporation, and
- make recommendations, if required, to the Board of Directors with respect to the matters listed above.

MEETINGS

The CCGNC shall meet at least twice per year and more frequently as circumstances require. All members of the CCGNC should strive to be at all meetings. The CCGNC shall meet separately, periodically, with senior management and may request any member of the Corporation's senior management or the Corporation's outside counsel to attend meetings of the CCGNC or with any members of, or advisors to, the CCGNC. The CCGNC will also meet in camera at each of its regularly scheduled meetings.

Quorum for the transaction of business at any meeting of the CCGNC shall be a majority of the number of members of the CCGNC or such greater number as the CCGNC shall by resolution determine. The powers of the CCGNC may be exercised at a meeting at which a quorum of the CCGNC is present in person or by telephone or other electronic means or by a resolution signed by all members entitled to vote on that resolution at a meeting of the CCGNC. Each member (including the Chair) is entitled to one (but only one) vote in CCGNC proceedings.

Meetings of the CCGNC shall be held from time to time and at such place as a member of the CCGNC may request upon 48 hours prior notice. The notice period may be waived by a quorum of the CCGNC.

The CCGNC may delegate authority to individual members and subcommittees of its members where the CCGNC determines it is appropriate to do so.

INDEPENDENT ADVICE

In discharging its mandate, the CCGNC shall have the authority to retain (and authorize the payment by the Corporation of) and receive advice from special legal or other advisors as the CCGNC determines to be necessary to permit it to carry out its duties. The CCGNC shall have the sole authority to appoint and, if appropriate, terminate any consultant used to identify director candidates and to approve the consultant's fees and other retention terms.

ANNUAL EVALUATION

Annually, the CCGNC shall, in a manner it determines to be appropriate:

- Conduct a review and evaluation of the performance of the CCGNC and its members, including the compliance of the CCGNC with this Charter.
- Review and assess the adequacy of its Charter and the position description for its Chair and recommend to the Board of Directors any improvements to this Charter or the position description that the CCGNC determines to be appropriate.

SCHEDULE 5

NUVO PHARMACEUTICALS INC. (the “Corporation”)

CHAIR OF THE COMPENSATION, CORPORATE GOVERNANCE AND NOMINATING COMMITTEE

POSITION DESCRIPTION

The Chair is a member of the Compensation, Corporate Governance and Nominating Committee (the “CCGNC”), designated by the Board of Directors to assist the CCGNC in fulfilling its duties effectively and efficiently in accordance with the written charter of the CCGNC.

The Chair will provide leadership to the CCGNC in discharging its mandate as set out in the Charter, including by promoting:

- a thorough understanding by members of the CCGNC and senior management of the duties and responsibilities of the CCGNC, and
- cohesiveness among members of the CCGNC.

The Chair shall be the liaison between the CCGNC, the Board of Directors and the Corporation’s senior management, promoting open and constructive discussions between members of the CCGNC and each of these parties.

In connection with meetings of the CCGNC, the Chair shall be responsible for:

- recommending procedures to enhance the work of the CCGNC,
- taking the principal initiative in scheduling meetings of the CCGNC,
- organizing and presenting the agenda for CCGNC meetings such that:
 - all of the responsibilities assigned to the CCGNC under the terms of its Charter are discharged on a timely and diligent basis, and
 - members of the CCGNC have input into the agendas,
- monitoring the adequacy of materials provided to the CCGNC by senior management in connection with the CCGNC’s deliberations,
- ensuring that members of the CCGNC have sufficient time to review the materials provided to them and to fully discuss the business that comes before the CCGNC, and
- presiding over meetings of the CCGNC.

On an annual basis, the Chair will facilitate:

- the performance review and evaluation of the CCGNC and its members in accordance with the Charter, and
- a review and assessment of the adequacy of the Charter and this position description, and following such review and assessment, make a recommendation to the Board of Directors with respect to any changes the CCGNC deems appropriate.

The Chair shall perform such other functions as may be ancillary to the duties and responsibilities described above and as may be delegated to the Chair by the CCGNC or the Board of Directors from time to time.

SCHEDULE 6

NUVO PHARMACEUTICALS INC. (the “Corporation”)

AUDIT COMMITTEE CHARTER

PURPOSE

The purpose of the Audit Committee (the “Committee”) is to assist the Board of Directors of Nuvo Pharmaceuticals Inc. (the “Board”) in fulfilling its responsibilities of oversight and supervision of the accounting and financial reporting practices and procedures, the adequacy of internal accounting controls and procedures and the quality and integrity of the consolidated financial statements of Nuvo Pharmaceuticals Inc. (the “Company”) and its affiliates. The Committee is also responsible for the audit process.

More specifically the purpose of the Committee is to satisfy itself that:

- A. The Company’s annual financial statements are fairly presented in accordance with Canadian generally accepted accounting principles and to recommend to the Board whether the annual financial statements should be approved.
- B. The information contained in the Company’s quarterly financial statements, annual report and other financial publications, such as management’s discussion and analysis, is complete and accurate in all material respects and to recommend to the Board whether these materials should be approved.
- C. The Company has appropriate systems of internal control over the safeguarding of assets and financial reporting to ensure compliance with legal and regulatory requirements.
- D. The external audit functions have been effectively carried out and that any matter which the independent auditors wish to bring to the attention of the Board has been addressed. The Committee will also recommend to the Board the re-appointment or appointment of auditors and their remuneration.

COMPOSITION AND TERMS OF OFFICE

- A. Following each annual meeting of the Company, the Board shall appoint three or more directors to serve on the Committee. Such appointees shall not be officers or employees of either the Company or its affiliates. Each member of the Committee must be “Independent” as defined by Multilateral Instrument 52-110 and “Unrelated” according to the rules of the Toronto Stock Exchange (the “TSX”) from time to time, and free of any relationship that could, or could reasonably be perceived to, in the opinion of the Board, interfere with the exercise of independent judgment as a member of the Committee. All members of the Committee must be financially literate and be able to read and understand fundamental financial statements that present a breadth and level of complexity of accounting issues that are generally comparable to the breadth and complexity of the issues that can reasonably be expected to be raised by the Company’s financial statements including the Company’s balance sheet, income statement and cash flow statement, or develop that capability within a reasonable time after appointment.
- B. The chair of Committee shall be appointed by the Board and shall not be an officer or employee of the Company or its affiliates. The chair of the Committee shall be a “financial expert” having an understanding of GAAP and financial statements, internal controls and procedures for financial reporting and, if possible, shall have served as the principal financial officer for another business entity.
- C. Any member of the Committee may be removed or replaced at any time by the Board and shall cease to be a member upon ceasing to be a director of the Company. Each member of the Committee shall hold office until the close of the next annual meeting of the Company or until the member resigns or is replaced, whichever first occurs.

- D. The Committee will meet at least four times per year. The meetings will be scheduled to permit timely review of the interim and annual financial statements of the Company and its affiliates. Additional meetings may be held as deemed necessary by the chair of the Committee or as requested by any member of the Committee or by the external auditors.
- E. If all members consent, and proper notice has been given or waived, a member or members of the Committee may participate in a meeting of the Committee by means of such telephonic, electronic or other communication facilities as permit all persons participating in the meeting to communicate adequately with each other, and a member participating in such a meeting by any such means is deemed to be present at that meeting.
- F. A quorum for the transaction of business at all meetings of the Committee shall be a majority of the members of the Committee. Questions arising at any meeting shall be determined by a majority of votes of the members of the Committee present, and in case of an equality of votes the Chair of Committee shall have a second casting vote.
- G. The Committee may invite such directors, officers and employees of as it may see fit from time to time to attend meetings of the Committee and assist in the discussion and consideration of the business of the Committee, but without voting rights.
- H. The Committee shall keep regular minutes of proceedings and shall cause them to be recorded in books kept for that purpose, and shall report the same to the Board at such times as the Board may, from time to time, require.
- I. Supporting schedules and information reviewed by the Committee will be available for examination by any director upon request to the Secretary of the Committee.
- J. The Committee shall choose as its secretary such person as it deems appropriate.
- K. The external auditors shall be given notice of, and have the right to appear before and to be heard at, every meeting of the Committee, and shall appear before the Committee when requested to do so by the Committee.

DUTIES AND RESPONSIBILITIES

Subject to the powers and duties of the Board, the Board hereby delegates to the Committee the following powers and duties to be performed by the Committee on behalf of and for the Board:

Financial Reporting Control

The Committee shall:

- (a) review reports from senior officers of the Company, outlining any significant changes in financial risks facing the Company;
- (b) review the management letter of the external auditors and responses to suggestions made;
- (c) annually review the Audit Committee Charter and the performance of the Committee itself;
- (d) review any new appointments to senior positions of the Company or its affiliates, with financial reporting responsibilities; and,
- (e) obtain assurance the external auditors regarding the overall control environment and the adequacy of accounting system controls.

Interim Financial Statements

The Committee shall:

- (a) review interim financial statements with officers of the Company prior to their release and recommend their approval to the Board. This will include a detailed review of quarterly and year-to-date results; and
- (b) review the Company's MD&A and press releases accompanying interim financial statements.

Annual Financial Statements and Other Financial Information

The Committee shall:

- (a) review any changes in accounting policies or financial reporting requirements that may affect the current year's financial statements;
- (b) obtain summaries of significant transactions and other potentially difficult matters whose treatment in the annual financial statements merits advance consideration;
- (c) obtain draft annual financial statements in advance of the Committee meeting and assess, on a preliminary basis, the reasonableness of the financial statements in light of the analyses provided by officers of the Company;
- (d) review a summary provided by the Company's general counsel of the status of any material pending or threatened litigation, claims and assessments;
- (e) discuss the annual financial statements and the auditors' report thereon in detail with officers of the Company and its auditors;
- (f) review the annual report and other annual financial reporting documents including management's discussion and analysis and press release;
- (g) provide to the Board a recommendation as to whether the annual financial statements should be approved;
- (h) review insurance coverage including directors' and officers' liability coverage ; and
- (i) review the Company's Annual Information Form ("AIF") and ensure compliance with FORM 52-110F1, audit committee information required in an AIF.

External Audit Terms of Reference, Reports, Planning and Appointment

The Committee shall:

- (a) ensure that the external auditor explicitly acknowledges that they are ultimately and directly accountable to the Board and the Committee as representatives of the shareholders;
- (b) review the audit plan with the external auditors;
- (c) specify its expectations of the external auditors, including the expected relationship between the external auditors and the Committee;
- (d) discuss in private with the external auditors matters affecting the conduct of their audit and other corporate matters, including:
 - the quality (not only acceptability) of Canadian GAAP accounting principles;

- the quality of internal controls;
 - the appropriateness of financial statement disclosures; and
 - any other matters the external auditors may wish to bring to the attention of the Committee.
- (e) recommend to the Board each year the retention or replacement of the external auditors. This process shall include establishment of criteria for and an ongoing assessment of the continued independence of the external auditor. If there is a plan to change auditors, review all issues related to the change and the steps planned for an orderly transition; and
- (f) annually review and recommend for approval to the Board the terms of engagement and the remuneration of the external auditors.

Other Matters

The Committee shall:

- (a) pre-approve all non-audit services to be provided to the Company or its subsidiary entities by the issuer's external auditor.
- (b) establish procedures for the receipt, retention and treatment of complaints received by the issuer regarding accounting, internal accounting controls, or auditing matters; and
- (c) establish procedures for the confidential, anonymous submission by employees of the issuer of concerns regarding questionable accounting or auditing matters.

ACCOUNTABILITY

- A. The Committee shall report to the Board at its next regular meeting all such action it has taken since the previous report.
- B. The Committee is empowered to investigate any activity of the Company and all employees are to cooperate as requested by the Committee. The Committee may retain persons having special expertise to assist it in fulfilling its responsibilities.
- C. The Committee is authorized to request the presence at any meeting, but without voting rights, of a representative from the external auditors, senior management, legal counsel or anyone else who could contribute substantively to the subject of the meeting and assist in the discussion and consideration of the business of the Committee, including directors, officers and employees of the Company.

SCHEDULE 7

NUVO PHARMACEUTICALS INC. (the “Corporation”)

CHAIR OF THE AUDIT COMMITTEE

POSITION DESCRIPTION

The Chair is a member of the Audit Committee, designated by the Board of Directors to assist the Audit Committee in fulfilling its duties effectively and efficiently in accordance with the written charter of the Audit Committee.

The Chair will provide leadership to the Audit Committee in discharging its mandate as set out in its Charter, including by promoting:

- a thorough understanding by members of the Audit Committee and senior management of the duties and responsibilities of the Audit Committee, and
- cohesiveness among members of the Audit Committee.

The Chair shall be the liaison between the Audit Committee, the Board of Directors and the Corporation’s senior management, promoting open and constructive discussions between members of the Committee and each of these parties.

In connection with meetings of the Audit Committee, the Chair shall be responsible for:

- recommending procedures to enhance the work of the Committee,
- taking the principal initiative in scheduling meetings of the Audit Committee,
- organizing and presenting the agenda for Audit Committee meetings such that:
 - all of the responsibilities assigned to the Audit Committee under the terms of its Charter are discharged on a timely and diligent basis, and
 - members of the Audit Committee have appropriate input into the agendas,
- monitoring the adequacy of materials provided to the Audit Committee by senior management and the independent auditors in connection with the Audit Committee’s deliberations,
- ensuring that members of the Audit Committee have sufficient time to review the materials provided to them and to fully discuss the business that comes before the Audit Committee, and
- presiding over meetings of the Audit Committee.

On an annual basis, the Chair will facilitate:

- the performance review and evaluation of the Audit Committee and its members in accordance with the Charter, and
- a review and assessment of the adequacy of the Charter and this position description, and following such review and assessment, make a recommendation to the Board of Directors with respect to any improvements the Audit Committee deems appropriate.

The Chair shall perform such other functions as may be ancillary to the duties and responsibilities described above and as may be delegated to the Chair by the Audit Committee or the Board of Directors from time to time.